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Summary 
 
In biomedical research involving time-to-event data, individuals may be 
susceptible to several possible outcomes. When an individual experiences more 
than one event in the follow-up process, this gives rise to multiple failure time 
data. In the modeling of such data, a random effect or „frailty‟ term is often 
introduced to accommodate the dependence between event times. In this paper, we 
consider a semi-competing risks framework, where a subject may experience two 
distinct types of events - terminal or non-terminal. In particular, the terminal event 
censors the non-terminal event but not vice versa. We propose frailty modeling for 
such data, where the frailty corresponds to an unknown subject-specific quantity 
which affects both events, leading to a dependence in their times of occurrence. 
Given frailty, a three-path compartment model is used to describe such data. We 
investigated the dependence structure between the events, as well as the covariate 
effects on each event. Extensive simulation studies were conducted to assess the 
performance of the proposed method. We also applied our methodology to data 
from a randomized clinical trial of nasopharyngeal cancer, where a positive 
dependence between recurrence and death was observed, indicating that relapse 
quickens the occurrence of death. This indicates that the association between non-
terminal and terminal events needs to be taken into account, so as to achieve more 
accurate estimates, as shown in our study.  
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0BChapter 1: Introduction  
 
 
8B1.1 Competing risks 
 
Time-to-event data, which is usually encountered in prospective studies, 
are often handled using some form of survival analytical methods. In such studies, 
an individual provides follow-up information on the time-to-event of interest and 
the censoring indicator denoting whether or not the event has occurred. P
1
P However 
in clinical trials comparing therapeutic interventions involving multiple survival 
outcomes, a subject may experience several distinct types of failures. This type of 
data is commonly referred to as competing risks. A competing risk can be defined 
as an occurrence which may preclude the onset of the event of interest, or may 
modify the probability of the onset of the event of interest.P
2
P A special case of 
competing risks occurs if only the first of all possible outcomes is observed, with 
all other outcomes being competing events.  
 
Competing risks data can arise under various circumstances with different 
research objectives. One possible research aim will be to analyze how different 
events can occur in a disease process, without any specific interest in a particular 
outcome. For example, investigators may be interested in examining different 
responses that can occur in patients with respect to changing drug dosage in a 
treatment process, such as in a study looking at how cerebral blood flow changes 
with different dosages of inhaled xenon gas in xenon CT scanning. P
3
P Alternatively, 
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investigators may be interested in the occurrence of a specific event, with all other 
types of events being regarded as interferences or competing events in the process 
leading to the event of interest. As an example, investigators may be interested in 
comparing the incidence of distant metastasis between chemo-radiotherapy and 
radiotherapy in a nasopharyngeal clinical trial. P
4
P While some subjects may have 
experienced distant metastasis, others have experienced competing events such as 
local recurrence or intercurrent death as a first event. Further examples of 








Event of interest Possible competing risks 
Local relapse  Relapse at other sites or death 
without local relapse 
 
Distant relapse  Relapse at other sites or death 
without distant relapse 
 




Cardiovascular death  non-vascular 
death, non-fatal stroke and angina 
 
In the analyses of clinical trials involving time-to-event outcomes, disease-
free and overall survival distributions are often presented to provide an insight of 
treatment efficacy.P
5
P While overall survival gives an indication of how long a 
patient survives from randomization till death, disease-free survival gives an idea 
of how long a patient survives without any disease symptom till a relapse or death. 
It is no doubt that relapse is the only event we can influence by treatment P
6
P, and 
that it is also biologically plausible that the time to relapse is strongly correlated 
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with the time to death (i.e. the occurrence of relapse quickens the death process). 
Hence, it is of interest to investigate how treatment affects the chance of relapse, 
bearing in mind that an assessment of the effect of a particular intervention on 
relapse should not be isolated from its effect on progression to mortality, since 




9B1.2 Semi-competing risks 
 
If all types of failures are allowed to be observed until possibly censored 
for each subject, multivariate failure time data arises. However, an analysis of 
multivariate failure time data involving possible recurrent events may be 
complicated by dependent censoring from terminal events such as mortality or 
informative dropout. Events occurring due to this data structure are sometimes 
referred to as semi-competing risks, where a terminal event can censor a non-
terminal outcome, but not vice versa.P
7
P In contrast to the approach adopted in the 
popular competing risks methodology where only the first event is of interest, 
semi-competing risks considers all possible occurrences of events in a natural 
disease process. For example, if death (a terminal event) occurs earlier, it will 
preclude the occurrence of relapse (a non-terminal event). However if relapse 
occurs earlier, both relapse and death may be observed.  
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Where multiple events are observed, it may be of interest to estimate and 
compare treatment efficacy for every outcome, with emphasis on the intermediate 
event. The importance of understanding how therapeutic interventions can bring 
about the occurrence of an intermediate event is underscored by Fine.
7
 In the 
context of allogenic bone marrow transplants in leukemia patients, “the 
distribution of time without relapse corresponds to a setting where death from 
graft versus host disease is preventable”.7P In such instances, patients can either die 
following a relapse or following graft versus host disease (GVHD). Hence, it will 
be interesting to understand how bone marrow transplants affect the risk of relapse, 
GVHD, and death after the occurrence of these intermediate events. It will also be 
valuable to know the extent to which relapse hastens the occurrence of death. 
 
Currently, literature on semi-competing risks data is limited; and 
competing risks methods are often used to analyze semi-competing risks data. 
Hence in order to appropriately account for the semi-competing risks data 
framework, analytical methods for estimating and modeling such data are 
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10B .3 Frailty 
 
 Most survival models assume that the risk of the study population for 
certain outcomes is homogeneous. However, the homogeneity assumption may 
not be valid as it is not possible to measure all covariates related to the disease of 
interest because of constraints in resources. The presence of unmeasured disease-
related covariates may result in a heterogeneous sample. Frailty accounts for the 
unexplained heterogeneity, which arises mainly due to related individuals or 
events, by introducing random effects into the survival models.P
8
P Examples of data 
describing related individuals are the Minnesota Twin Family Study which 
attempts to assess the impact of genetic and environmental effects on the 
development of psychological traits, Danish Twin Study, and the Twins and 
Multiple Births Association heritability study (TAMBAhs) in Birmingham.  
 
To elaborate on the meaning of frailty, consider multivariate survival data 
with possible correlation between clustered event times. In the context of survival 
times of related individuals, related individuals constitute a “cluster”. Where 
multiple events are observed for the same individual, the individual constitutes a 
“cluster”. Frailty models formulate the dependence of clustered event times by 
introducing a cluster-specific random effect, which is multiplicative on the 
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11B .4 Objectives and Outline of thesis 
 
 
24B1.4.1 Objectives  
 
Semi-competing risks data arises when both non-terminal and terminal 
events occur and are of analytical importance. In survival data, a non-terminal 
event and a terminal event usually refer to morbidity and mortality respectively. 
These two events are usually correlated; and censoring of morbidity by mortality 
is informative. Hence, in this thesis, we want to get a more precise estimate of the 
effect size (in particular, treatment effect) for each clinical outcome, and also to 
characterize the correlation between morbidity and mortality.  
 
We consider strategies for analyzing covariate effects by using frailty 
models to describe the dependence structure and to assess treatment efficacy with 
respect to the terminal and non-terminal events. The compartment model is further 
described in Chapter 3.  It is similar to an illness-death modelP
9
P, which describes 
the risk of moving from one disease-state to another. While the illness-death 
model may be bi-directional (that is, a patient can progress from the state of 
recovery after treatment to disease recurrence and vice versa), the compartment 
model is uni-directional (that is, the change in state is from recovery to disease 
recurrence only).  
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25B1.4.2 Outline 
 
 We have given a description of competing risks in the previous sections. 
Sections 1.1 and 1.2 describe the type of data giving rise to the analytical 
framework of competing and semi-competing risks respectively. Where multiple 
events of an individual can be observed and only the first event is considered, this 
analytical framework constitutes a special case and the most common form of 
competing risks data. If all data points are involved in the analysis, then other 
analytical procedures are required. Section 1.3 briefly defines what is meant by 
“frailty”. Section 1.4 presents the aims and outline of this thesis. Section 1.5 
illustrates terminologies and analytical procedures associated with competing risks. 
Section 1.6 summarizes the development of methodologies proposed specifically 
for analyzing semi-competing risks data. Section 1.7 discusses why current 
competing risks methodologies may not be suitable for semi-competing risks data. 
In addition, it addresses the limitations of semi-competing risks methods proposed 
thus far, and describes how our proposed method can resolve some of these 
limitations. 
 
Chapter 2 illustrates the use of existing methods for semi-competing risks 
data with some clinical examples. Chapter 3 gives an overview of the proposed 
compartment model. The formulation of each path in the compartment model is 
explicitly characterized in this chapter, together with the algorithm used to derive 
the parameter estimates. In the same chapter, we also suggest a graphical method 
for checking the adequacy of the model. In Chapter 4, simulation studies are 
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conducted to evaluate the performance of the proposed model. Treatment effects, 
association between terminal and non-terminal outcomes, censoring proportions 
and sample sizes are varied to investigate their impact on the model. Results 
relating to the precision of the parameter estimates are presented and discussed. 
Chapter 5 applies the proposed method to a nasopharyngeal cancer clinical trial 
(NPC) dataset. We quantify the dependence between relapse and death, as well as 
compare the treatment effects (chemo-radiotherapy versus radiotherapy) on 
relapse and death respectively. In addition, adequacy of the overall model fit to the 
NPC data is checked. Finally, Chapter 6 summarizes and provides some 
discussion on the compartment model approach for analyzing semi-competing 
risks data. Further scope for future work extending our proposed method, is also 
discussed in this chapter.  
 
 




P (KM) estimator is commonly used to report disease-
free and overall survival distributions. However, when competing risks exist, this 
approach may not be an appropriate measure for estimating the survival 
distribution of the primary event. An example involves distant recurrence as the 
primary event and local-regional recurrences as the competing type of failure. The 
Kaplan-Meier approach assumes that censoring is non-informative, that is,  the 
censoring mechanism is independent of the event of interest. P
2
P Hence, the 
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application of the KM method for estimating event-specific probability of 




 Referring to the nasopharyngeal clinical trial described in Section 1.1, it 
was observed that distant relapse was the most frequent site of first relapse (38 out 
of 48 first relapses were distant in R and 18 out of 27 in CRT).P
4
P Thus, it was of 
interest to examine the incidence of distant metastasis. However, other competing 
events, such as loco-regional recurrence or death, may preclude the observation of 
distant metastasis. Therefore, the assumption of non-informative censoring under 
the naive KM approach may not be appropriate in this study since it is anticipated 
that the occurrence of loco-regional recurrence may have an effect on distant 
metastasis, and vice versa. For instance, the occurrence of loco-regional 
recurrence may indicate a more rapid development of distant metastasis, should 
the course of treatment remain status quo. This change in risk for distant 
metastasis, after an occurrence of loco-regional recurrence, indicates a 
dependency between loco-regional recurrence and distant metastasis. Furthermore, 
if death occurs first, it will inherently prevent any future observation of distant 
metastasis. However, the KM method censors competing events and treats the 
occurrence of the competing events (death and loco-regional recurrence) as though 
they do not alter (or add information to) the probability of observing distant 
metastasis.  
 
 In view of the limitations of KM for analyzing competing risks data, 
appropriate tools were developed. In general, there are 2 approaches for analyzing 
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competing risks data. They are namely, the bivariate random variable and multiple 
decrement model methods, which are described in greater detail below.  
 
UBivariate random variable 
In this approach, time-to-event data is represented by the pair (T, C) for 
each individual, where T ≥ 0 is the observation time of the first event and C 
indicates the type of event which occurs at time T = t. C takes on a value of 0 if 
the observation is censored administratively, and i (i = 1, 2, …, p) if the first event 
that occurs is of type i.  
  
In the presence of competing risks, the corresponding cause-specific 
hazard (CSH, ( )ih t ), which describes the instantaneous rate of occurrence of the 
iP
th
P event at time t given covariate X, is written as 
0
Pr( , | , )
( ) lim{ }i
t





    
  
 
 The cumulative incidence function (also called sub-distribution) is used to 
describe the probability that the iP
th
P event occurs before or at time t (CIFRiR), given X. 
It is expressed as  
( | ) Pr( , | )iCIF t X T t C i X    
 
CSH is different from the hazard of the sub-distribution (also called sub-
hazard) introduced by Gray (1988)P
12
P. For the iP
th
P event, the sub-hazard is defined 
as 
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0
Pr( , | ( ) ( ), )




















Where fRiR(t|X) and SRiR(t|X) are the sub-density and survival functions of the sub-
distribution respectively.  
 
This construction of the hazard function may sound “unnatural”, since it 
takes individuals who have failed from causes other than cause i before time t into 
its computation. However, in reality, individuals who have failed from cause j ≠ i 
may not be at risk of cause i at time t. Hence, this could lead to a difficulty in 
interpreting an individual‟s risk of failure from cause i at time t if he has died from 
other causes at time t - 1.  
 
While Gray‟s sub-hazard is introduced mainly to allow for testing and 
modeling of covariate effects, other tests for equality for cumulative incidence 




P.   
 
 
UMultiple decrement model   
 In this approach, a multivariate survival model is used to analyze 
competing risks data, where each individual is assumed to have a potential time to 
event. An observation time T =  1 2min , ,  , pT T T  is defined, supposing that 
there are potentially p causes of failure and iT  is the time to the iP
th
P event where i = 
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1, 2, …, p. When the first event is observed, the times to the other remaining 
events are considered to be latent.  
 
 Given covariate effects X, a joint survival function (also known as the 
multiple decrement function) can be written as 
1 2 1 1 2 2( , ,..., ; ) Pr( , ,..., ; )p p pS T T T X T t T t T t X    . As it is still not clear how  
time-dependent effects may be incorporated in this multivariate model, covariate 
effects are assumed to be time-invariant.  
 
 Correspondingly, the sub-hazard for the iP
th
P event ( )i t and cause-specific 




Pr( , | ; )
( ) lim{ }







t T t t C i T t X
t
t
S t t t X
t










   
 
and 










 It is noted that functions of 1 2( , ,..., ; )pS T T T X , which cannot be expressed 
in terms of the cause-specific hazards, are generally non-identifiable. One example 
is the marginal function of the latent failure time, which cannot be estimated from 
the data without making any assumption. The marginals can only be estimated by 
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assuming that event times are independent, so that the cause-specific hazard will 
be equal to the hazard of the marginal function for each event type.  
 
 
UChoice of method for competing risks data 
The choice of analytical method depends on the research question. If the 
objective of a study is to test if a covariate has any impact on the biological 
mechanism, it is suggested that the multiple decrement model be used. Results 
drawn from this model apply to a virtual world where competing risks are absent. 
In contrast, the bivariate random variable approach will probably be preferred if it 







13B .6 Current methods proposed for semi-competing risks data 
 
There is currently limited literature for semi-competing risks dataP
7,18,19
P In 
order to evaluate the dependence structure between non-terminal and terminal 
event times, Fine et al. formulated the Clayton or gamma frailty copula model in 
the upper wedge where Y1R (time to non-terminal event) ≤ Y2 (time to terminal 
event)
7
P A copula is a function which associates a bivariate distribution function 
),( 21 yyH  to its one-dimensional marginal distribution functions )( 1yF  and 
)( 2yG  defined by the relationship ))(),((),( 2121 yGyFCyyH  P
20
P This means that 
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a copula is a multivariate distribution function defined on the space [0, 1] P
p
P such 
that each of its p marginal distribution follows a uniform distribution on [0, 1]. 
Fine et alP
7,18
P utilizes the marginal distribution of the non-terminal event under 
weaker, but similar assumptions, to those used in multiple decrement models for 
competing risks. Within the observable region of YR1 R≤ YR2R, the joint survival 





1 ySyS YY  where θ ≥ 
1 and 0 ≤ YR1 R≤ YR2 R≤ ∞. )( 11 ySY and )( 22 ySY are marginal survival functions for the 
times to the non-terminal and terminal events respectively.  
 








 YR2R is observed, but  
YR1R is censored by YR2 
Both YR1R and YR2R are censored administratively. (?) 




and YR2R are 
observed. 
Arrow indicates direction of censoring. 
YR2 
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Since the joint survival function originates from the gamma frailty model, 
there are nice properties associated with it. For example, the association parameter 
in the Clayton‟s copula can also be interpreted as the predictive hazard ratio which 
measures the relative risk of death to relapse, apart from measuring the degree of 
dependence between the times to terminal and non-terminal events. In addition, it 
is associated with the conditional Kendall‟s tau, which is yet another measure of 
correlation.P
21
P The appropriateness of the Clayton model on the upper wedge is 
important since inferences pertaining to the marginal survival function of the non-
terminal event time rely on the model specification in the observable region. 
Hence, checking of model adequacy is performed through an extension of Oakes‟ 
estimatorsP
22,23
P A goodness-of-fit statistic can be obtained from the distance 
between two estimators from U(θ) with different weights W(.), where  
~ ~








    

 .  
For q and v = 1, …, N subjects, the parameters in U(θ) are described as follows: 
~ ~ ~ ~
1 2,,
min( , , )qv qvqv qvS Y Y C
, 
~ ~ ~
2,min( , )qv ijqvR Y C
,  
~ ~ ~ ~
1, 2,( )qv qvqv qvB I Y Y C  
, 
1, 1, 2, 2,{( )( ) 0}qv q v q vI Y Y Y Y     ,  
~
1 1, 1,,
min( , )q vqvY Y Y  and 
~






P has shown that the estimates are robust to the misspecification 
of the copula. The Clayton model may provide a reasonably good approximation 
to other popular classes of distributions, such as the bivariate exponential, 
bivariate log-normal and Gumbel copulaP
25
P  
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It was not known how covariates influence the relationship between a non-




P considered the testing 
of constant dependence across strata of a discrete covariate, by evaluating whether 
the dependence between the non-terminal and terminal event is the same for both 
treatment and placebo groups. Hypothesis testing of constant dependence on the 
























1 1 1 1 1 1 2
0
1
( | ) lim Pr( | , )Y
y
d




      and (0, )H   . YR1R and YR2R are 
the times to the non-terminal and terminal events respectively. 
  
Hence, the null hypothesis that the dependence between the two event 
times is constant across levels of a discrete covariate can be written as: 






( | , )
( , | )




y Y y D d
y y D d







 and d corresponds to the level of the 
covariate. 
 
Testing the above hypothesis is also the same as testing for interaction 
between the covariate X and the association parameter θ in the observable region 
of the event times. However, it is noted that the above test is only valid if the 
Clayton gamma frailty copula model was true. Therefore, the appropriateness of 
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While the degree of dependence between event times has been analyzed 
via the non-parametric concordance statistic, Dignam et al
26
P exemplified 
dependence between event times by using parametric models based on complete 
pairs of Y1 and Y2 event times. The marginal distributions are estimated by treating 
censored/ unobservable Y1‟s as missing data. EM algorithm was used to estimate 
the parameters governing the forms of the survival function of Y1 and of the 
survival function of Y2 conditional on Y1. However, the form of the dependence 
structure between Y1 and Y2 was not explicitly characterized in their paper. 
 
Although the Clayton copula has generally been used for semi-competing 
risks data, it may not be suitable for certain data structures. However, 
modifications can be made to it depending on the type of data. This is shown in 
JiangP
27
P where the Clayton‟s copula model was modified into a conditional one for 





1 2{ ( ) ( ) 1}Y YS y S y
      where θ ≥ 1 and 0 ≤ YR1 R≤ YR2 R≤ ∞ as postulated above, 
the model was modified as  
1
11 1
1 2{ ( ) ( ) 1}a aR y S y
     where 2( )aS y is the 
conditional survival function given that YR2R is greater than a, and 1( )aR y is the 
survival function conditional on YR1R greater than a and dependent censoring by YR2R. 
The Lynden-Bell estimator was constructed to estimate marginal survival function 
for the non-terminal and terminal events under mild assumptions. It is a product-
limit estimator derived from non-parametric maximum likelihood arguments for 
truncated data Y1,nR, which is observable only if Y1,n ≥ YR2,n for n = 1, 2, …, N 
subjects. It is denoted as 
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28,29
P However, it was noted that the Lynden-Bell 
estimator may not be appropriate for the survival function for the non-terminal 
event, as the estimator may not be monotone or well-defined. This phenomenon 
occurs especially in its tail of the survival distribution where heavy censoring by 
the terminal event usually occurs. Therefore, restriction of the estimation interval 
was put in place to circumvent the problem. To reiterate, the conclusions inferred 
will be valid if (1) the copula model describing the joint survival functions of the 
non-terminal and terminal event times was correctly specified, and (2) the survival 
function for the non-terminal event defined on the upper wedge where Y1 R≤ Y2 
Rcorresponds to the marginal of Y1 Rdefined on the lower wedge YR1 ≥ Y2R, where no 
data can be observed.  
 
 The conventional Clayton copula model could also be extended into a 
time-dependent copula, characterizing the correlation between events, to capture 
the informative censoring of Y2 Ron Y1. Knowledge of the impact of covariate 
effects on event times could be evaluated through a regression model. Non-linear 
estimating equations were used to solve for the parameter estimates. In addition, 
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So far, all estimations made for the marginal distribution of the non-
terminal event time were formulated based on the framework of the Clayton 
gamma frailty copula. Besides looking at the estimation of the survival function of 
the non-terminal event, other authors have looked at areas which included 
generalizing the semi-competing approach to include other copulas and to make 
inferences in terms of hypothesis testing. For instance, Lakhal et al generalized 
Fine‟s approach by illustrating that the semi-competing risks idea could be applied 
to all Archimedean copulas through simulations and applying them to study the 
correlation between times to relapse and death in patients with bone marrow 
transplantsP
21
P An Archimedean copula is a function C which maps [0, 1] P
2
P to [0, 1] 
given by C(u, v) = ψP[-1]P(ψ(u)+ ψ(v)), where ψ is called the generator of C. ψ is a 
continuous monotonic decreasing convex function which maps [0, 1] to [0, ∞] 
such that ψ(1) = 0 and ψ(0) = ∞. ψP[-1]P is the pseudo-inverse of ψ, which means that 
ψP[-1]P(y) = ψP-1P(y) where y is an element in [0, ψ(0)] and ψP[-1]P(y) = 0 for y ≥ ψ(0).P20P 
Most of the Archimedean copulas, which include the Clayton, Gumbel and Frank 





 have also implemented Archimedean copulas in the analyses of semi-
competing risks data. However, in their paper, they have suggested the use of 
separate Archimedean copula models for each covariate group while maintaining a 
monotonically increasing hazard function for the disease progression time under 
dependent censoring. Model checking and selection via bootstrap methods are also 
proposed.P
30
P Subsequently, Xu et alP
31
P argued that the notion of latent failure times 
is entertained in previous approaches since they  usually construct mathematical 
models in both the observable and unobservable regions of the data. Hence, they 
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proposed a model constructed within the observable region of the data to 
accommodate covariates. In addition, frailty was used to account for the correlated 
endpoints (morbidity and mortality). Non-parametric maximum likelihood 
methods were used to estimate the parameters. 
 
Thus far, methods concerning semi-competing risks data have been 
discussed in the context of the copula function. It is also possible to consider 
solving for parameter estimates in relation to this type of data via a multi-state 
modeling approach as in Siannis et alP
32
P Using this approach, a continuous time 
model with Weibull time-varying hazards, assuming that transition rates depend 
only on the last state visited but not on the complete history of transitions, was 
adopted. The time for each subject used in the analysis was measured from the 
time since entry into the study to the starting time in the current state. It will be 
less appropriate to consider the analysis time as the time taken to travel in between 
any 2 states, i.e. having to reset to zero the time axis after the subject enters into a 
state, since the hazards vary with time. In addition, it was noted that estimates of 
the transition rates starting from censored events to a terminal event would be 
correlated and no unique solution of the likelihood would exist, without further 
model assumptions, in general.  
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14B .7 Limitations of existing methods for semi-competing risks data 
 
Competing risks methods have often been used for analyzing semi-
competing risks data. The first-event methodology adopted in competing risks 
analysis is based on the premise that upon removal of one of the failures, the risks 
of failure on the remaining causes remain unchanged. That is, the development of 
the event of interest is independent of the progression of competing risks. In 
particular, the classical competing risk framework in which a subject may only fail 
from one of several distinct causes will probably be more applicable in a situation 
with several absorbing states. One such example, which considers death due to 
disease as the event of interest and death due to other causes as the competing risk 
event, is illustrated below.   
 
 While the first-event methodology will be appropriate for competing risks, 
it may not be the most suitable method for a data structure involving endpoints 
which follow a natural occurrence of events. Specifically in such naturally ordered 
 
Treatment 
Death due to 
disease 
Death due to 
other causes 
UCauses of failure: 
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data involving a terminal event (death) and non-terminal event (recurrence), death 
has the ability to preclude the occurrence of recurrence but not the other way 
round. Then, censoring from mortality becomes informative. Furthermore, in this 
instance, it may be of interest to know the dependence structure between 
recurrence and death (and hence, to understand the predictive value of recurrence 
for death). The use of the first-event approach limits our ability to do so since 
subsequent events after the first would not form part of the data analyzed.  
 
In order to utilize all subsequent events that occurred after the first so as to 
describe the data sufficiently, methods based on the weak assumption of marginals, 
which accounts for the dependence structure between all the occurrences of 
endpoints, have been proposed. They have been described in Section 1.6. In 
general, authors working on semi-competing risks methodology have considered 
variations within the basic model structure. These variations include the different 
types of copulas used to characterize the dependence between the non-terminal 
and terminal events, as well as the different types of survival models which can be 
used to describe the mathematical functions of the non-terminal and terminal 
events. Approaches, which could be used to incorporate covariates and to perform 
hypothesis testing, were also proposed.  
 
However, as pointed out by Xu et alP
31
P, these methods implied a kind of 
model formulation using latent times. Hence, the authors have proposed 
mathematical models which are constructed within the observable region of the 
event times. The models also allowed for varying hazards and treatment effects 
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depending on whether the non-terminal event has occurred prior to the terminal 
event. It is a generalization of the previous models put forward by other authors 
who have assumed that the effect of the occurrence of a non-terminal event on the 
terminal event has been fully explained by the correlation between the two events. 
The correlation is characterized by the copula model incorporated into the basic 
model formulation.  
  
 In this thesis, the idea conceptualized by Xu et alP
31
P is extended. Based on 
the original compartment model framework proposed, data is modeled within the 
observable region, that is, no marginal distribution for the non-terminal event is 
assumed. In the previous article, baseline hazards were regarded as a “nuisance” 
parameter in the solution of covariate effects such as treatment. However, it may 
be of interest to know the form of baseline hazards apart from the covariate effects. 
Therefore, we attempt to characterize the baseline hazards via parametric 
modeling in this thesis. In addition, goodness-of-fit assessments of the models, 
which have not been recommended by Xu et alP
31
P, are proposed. The methodology 
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1.8 Contribution to medical research 
 
The work arising from this paper has been presented at the 29 P
th
P Annual 
Conference of the International Society for Clinical Biostatistics (Copenhagen, 
Denmark); as well as at a seminar in the Department of Medical Epidemiology 
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While the Kaplan-Meier and Cox proportional hazards model are popular 
methods used to analyze survival data without competing events, the bivariate 
random variable method involving implementation of the cumulative incidence 
function is often used in analyses of competing risks data. However, these tools 
may not be reasonable for semi-competing risks data, which are widely 
encountered in the medical field. To our knowledge, no clinical paper has 
implemented the existing methods as described in Section 1.6. Current approaches 




16B2.1 ATAC (Arimidex, Tamoxifen, Alone or in Combination) clinical 
trial 
 
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) randomized 
clinical trial involved 9366 postmenopausal women with localized breast cancer 
enrolled from 381 centers in 21 countries between 12 July 1996 and 24 March 
2000. The primary aim of the trial was to ascertain the efficacy of anastrozole 
(alone, or in combination with tamoxifen) as compared with tamoxifen alone. The 
primary endpoint was disease-free survival (DFS), which was defined as the time 
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to the earliest occurrence of local or distant recurrence, new primary breast cancer, 
or death due to any cause. Secondary endpoints were time to a recurrence which 
includes new contralateral tumors but not patients who died from non-breast 





 In this ATAC trial, both the log-rank test and Cox proportional hazards 
model were used to analyze disease-free survival (DFS) and outcomes under 
investigation based on an intention-to-treat approach. It was shown that as 
compared with women treated with only tamoxifen, DFS was significantly higher 
for patients on anastrozole (Hazard ratio, HR: 0.83; 95% CI: 0.71 - 0.96; p = 0.013) 
or a combination of anastrozole and tamoxifen (HR: 0.81; 95% CI: 0.70 - 0.94; p 
= 0.006). Figure 2 shows the Kaplan-Meier curves for DFS in the intention-to-
treat population.  
 
Figure 2: Kaplan-Meier curves depicting disease-free survival (i.e., all first 
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There did not seem to be a substantial difference in the number of patients 
who died (regardless of any cause of death) before a breast cancer recurrence 
(Table 2). When these patients were censored upon death, the hazards for the time 
to recurrence (including new tumors) in the anastrozole group was lower than the 
tamoxifen group (HR: 0.79; 95% CI: 0.67 - 0.94; p = 0.008). The benefit appeared 
to be comparable between the combination and tamoxifen groups (Figure 3). 
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Events at any time 













Deaths after recurrence 
 
122 122 145 389 
All deaths 200 203 215 618 
†: Includes 5 deaths (2 on anastrozole, 1 on tamoxifen, and 2 on the combination), which were attributed to 











 From Table 2, it was also noted that there was a substantial number of 
women who died after recurrence. Out of 618 deaths in the three treatment arms 
(Anastrozole, Tamoxifen and Combination), 389 of them (62.9%) occurred after 
recurrence. This indicated that recurrence could possibly quicken the occurrence 
of death. Furthermore, in a subsequent analysis of the trial data, there was a total 
of 831 deaths where 500 (60%) occurred after breast cancer recurrence and 331 
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(40%) without recurrence which was attributed to other causes P
34
P The considerable 
proportion of deaths after recurrence suggests that the predictive value of relapse 
for death is high. In this scenario, regarding death as a non-informative censoring 
mechanism for recurrence is likely to lead to a bias in the estimation of 
recurrence-free survival. Thus, it will be crucial to treat censoring of recurrence by 
death as being dependent so as to provide an accurate estimation of recurrence-
free survival. 
 
 Further, since the occurrence of death will inherently prevent any 
recurrence from being observed but not vice versa, a semi-competing risks data 




17B2.2 Hip fractures 
 
In a population-based study conducted to investigate the trend in 
recurrence of hip fractures, hip fractures that occurred among residents of the 
central city of Rochester from 1928 to 2006, and among residents of Olmsted 
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 The cumulative incidence of a second hip fracture was calculated among 
those with a first-ever hip fracture. In order to calculate the recurrence of hip 
fractures, 2 calculations were carried out in this study – the first which censored 
observation time upon death, and the second which treated death as a competing 
event. In addition, since fracture recurrence might be reduced among people 
treated with hip arthroplasty, observation time for these individuals was censored 
at the time an arthroplasty was performed.  
 
 Out of 2434 patients (1832 women and 602 men) with a first-ever hip 
fracture, 219 patients experienced recurrent hip fractures over a follow-up period 
of 10000 person-years. The median time from the first to the second hip fracture 
was 2.7 years for all patients, 2.8 years for women and 2.1 years for men.  
 
 In the first analysis which censored observation time upon death, the 
cumulative incidence of a second hip fracture was 29% for all patients, 32% for 
women and 18% for men. However, it was noted that there was a high death rate 
among the patients, which could result in an overestimation of recurrence rate. 
Hence in order to obtain a more realistic estimate for recurrence rate, a second 
analysis was performed treating death as a competing event. In this analysis, the 
estimated cumulative incidence of a second hip fracture was 12% for all subjects, 
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Figure 4: Cumulative incidence of a recurrent hip fracture among 2434 
patients who had a first-ever hip fracture in 1980–2006 with follow-up 







Hip fracture as an intermediate event does not preclude death from 
occurring, but when death occurs, it will inherently preclude any further 
observation of hip fractures; thereby fitting into the semi-competing risks 
framework. Approaches for semi-competing risks do not impose any assumption, 
but explicitly model the disease progression from hip fracture to death. All causes 
of death can be accommodated regardless of whether it is related to recurrent hip 
fractures. A schema of how the data for hip fractures and death is able to fit into 
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18B2.3 AIDS 
 
This example was derived from data of HIV-1 patients collected from the 
Concerted Action on SeroConversion to AIDS and Death in Europe 
(CASCADE).P
36
P The objective of the study was to assess the effect of gender on 
survival, progression to AIDS, as well as on the risk of developing each specific 
AIDS defining events (such as candidiasis, cryptococcosis, Kaposi‟s sarcoma, 
AIDS dementia complex, herpes simplex disease and HIV wasting syndrome) as 
first event and death without AIDS over time. The data was derived from a 
collaborative effort from 23 HIV seroconverter cohort studies in Europe, Australia 
and Canada. A total of 6923 subjects (3414 women and 3509 men) were entered 
into the study, where they were followed up from the latest of the three dates – 
seroconversion, entry into the cohort, and 1 December 1986.  
 
 In order to investigate the effect of sex on the progression to AIDS, as well 
as to each specific AIDS defining event as the event of interest, and death without 
AIDS as the competing event, modeling techniques involving cause-specific 
hazards and hazards of sub-distribution functions were used.  
 
 While there did not seem to be any gender differences in the progression to 
AIDS before 1997, females had a 24% (95% CI: 10 - 37) lower risk of developing 
AIDS as compared to the males after 1997, after adjusting for potential 
confounders - drug use via injections, sexual activity and age at seroconversion 
(Figure 5). Before 1997, there did not appear to be a prognostic value of gender on 
  - 39 -  
the risk of each specific AIDS defining event or death without AIDS, except for 
Kaposi‟s sarcoma where it was shown that females had a lower risk of developing 
the disease. After 1997, it was observed that females were at a lower risk of 
developing AIDS dementia complex, tuberculosis, Kaposi‟s sarcoma and 
lymphomas. Throughout the study period, females were at a lower risk of death 
without AIDS than men.  
 
Figure 5: Cumulative incidence of AIDS, stratified by calendar period (pre-
1997 and 1997–2006) and gender, CASCADE collaboration.P36P 
 
 
In this study, competing risks analyses were used in the examination of the 
progression to AIDS, AIDS defining events and death without AIDS. However, it 
was noted that the occurrence of death after AIDS have been captured in the 
CASCADE study. Thus, it will be interesting to see how covariate effects compare 
in terms of the prognostic outlook before and after the development of AIDS (or 
AIDS defining events). Although AIDS, AIDS defining event and death were 
outcomes which have been captured in the study, the manner in which these 
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outcomes relate to one another, such as the predictiveness of AIDS (or AIDS 
defining event) on death, has not been assessed. Hence, a semi-competing risks 
approach can be used to analyze the progression to AIDS, taking into account 
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In this chapter, we describe a new method for analyzing semi-competing 
risks data. A compartment model approach is proposed to describe survival 
experiences and to examine the effect of each prognostic factor for each possible 
endpoint encountered in a disease progression pathway, and to estimate the 
correlation between any two event types (non-terminal and terminal) for each 
subject. To facilitate the discussion of the proposed method, we assume that the 
only outcomes that can arise are relapse (non-terminal) and death (terminal). 
Without loss of generality, we also assume that there is only a single covariate of 
interest (treatment) in the discussion of our proposed methodology. 
 
 
19B3.1  Compartment model 
 
For subject n, where n = 1, ..., N, let YR1,nR and YR2,nR be the time to non-
terminal and terminal events respectively,. Both times are measured from the time 
since entry into the study to the occurrence of each event. By convention, we 
allow YR1,nR to take on the value of infinity if the non-terminal event does not occur 
prior to death. The administrative censoring time is denoted by CRnR and the 
treatment covariate by xRnR. The observations consist of TR2,nR = min(YR2,nR, CRnR), TR1,nR = 
min(YR1,nR,TR2,nR), δR2,nR = I(YR2,nR ≤ CRnR), δR1,nR = I(YR1,nR ≤ TR2,nR) and xRnR, for n = 1, …, N. I(.) 
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is an indicator function which takes on values 1 if the event occurs and 0 
otherwise.  
 
In order to characterize the correlation between morbidity and mortality for 
each individual in the proposed compartment model, semi-competing risks data 
are analyzed using frailty models, where the frailty is denoted by w. The frailties 
are assumed to be independently and identically distributed with probability 
density function (pdf) gRθR(w), which follows a gamma distribution with mean 1 and 



















θ could be re-parameterized into ePθ’P to ensure that θ is strictly non-negative. 



























Although the gamma frailty is used here, other frailty models could also be 
used in the framework of the proposed method. In this scenario, the popular 
gamma frailty model is assumed because of its mathematical convenience.  
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The compartment model shown below is used to describe the disease 
process. Given ωRnR, we assume that for the nP
th
P individual, the conditional hazards 
of the 3 paths are of the following forms:  
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(ii) Hazard for terminal event without prior occurrence of non-terminal event 
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(iii) Hazard for terminal event following the occurrence of a non-terminal event 
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In the above formulation, the covariate effect is incorporated through the 
Cox proportional hazards model for all 3 paths of the compartment model, with β 
representing the regression coefficient associated with the covariate vector xRnR. The 
baseline hazard associated with the non-terminal event is denoted by hR01R; and the 
baseline hazards associated with the terminal event without or after the occurrence 
of a non-terminal event are denoted by hR02R and hR03R respectively. Under this 
circumstance, it is assumed that frailty is unable to fully characterize the 
dependency between two very different types of events, namely relapse and death. 
Hence, a more general model, which accounts for possibly differing hazards of 
death depending on whether there was a prior occurrence of relapse (βR2 R≠ βR3R and 
hR02 R≠ hR03R), is used. We coin this as the “General compartment model”.  
 
When frailty fully accounts for the dependency between relapse and death 
(βR2 R= βR3R and hR02 R= hR03R), a “Restrictive compartment model” results. This is 




In this thesis, we discuss primarily the methodology of a General 
compartment model, since the Restrictive model is a special case of the former. 
The validity of a Restrictive model may also be assessed by testing if βR2 R= βR3R and 
hR02 R= hR03R simultaneously in the General compartment model using the likelihood 
ratio test.  
 
  In the General compartment model, the baseline hazard functions hR01R, hR02R 
and hR03R are assumed to be of Weibull form due to its wide applicability and 
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flexibility for survival data. We allowed hR01R, hR02R and hR03R to have different shape (γ) 
and scale (λ) parameters. To be more specific, the baseline hazard functions 
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The hazard is monotonically decreasing for γ < 1, increasing for γ > 1 and 
constant for γ = 1. The exponential distribution is a special case of the Weibull 
distribution when both λ and γ are equal to 1. Similar to the re-parameterization of 
θ, λs and γs can also be re-parameterized into ePλ’ and ePγ’ to ensure that the scale 
and shape parameters are non-negative. Then, the formulations in (A) will become 
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20B3.2   Likelihood estimation and algorithm 
 
Define 
1 1, 1 1,, exp{ , }| |( ) ( )n n n nn nx xw wS t H t  , 
2 1, 2 1,, exp{ , }| |( ) ( )n n n nn nx xw wS t H t   and 
03 2, 03 1, 33 2, 1, , , exp( ( ( ) ( )) ( ))|( )
T
n n n n n nn n w x H t H t w exp xS t t   , where tR1R and tR2R are 
the observed times.  
 
Conditional on the frailty wRnR, the likelihood L(λ, β, γ| w, x) from the 
observations {(tR1,nR, tR2,nR, δR1,nR, δR2,nR, xRnR), n = 1, …, N} is 
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Denote the parameters to be estimated by η = (θ, λR1R, γR1R, βR1R, λR2R, γR2R, βR2R, λR3R, 
γR3R, βR3R). 
 
 If the wRnR’s could be observed, the logarithm of the complete data 
likelihood is  
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Both the Newton-Raphson (NR) and the Expectation-Maximization (EM) 
algorithms can be used for parameter estimation. P
37
P NR, which is the method 
adopted to compute parameter estimates in this thesis, is elaborated as follows.  
 
 
26B3.2.1 Newton-Raphson method 
 
The Newton-Raphson (NR) method aims to find estimates that maximize 
the observed full likelihood of the data. Under our current model framework, the 
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observed full likelihood can be obtained after integrating the complete data 
likelihood over the space of the frailty variable wRnR. The observed full likelihood 
( | )fullL data is 
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 can be obtained by computing the row vector of first partial 















 as the observed 
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information matrix. Details for computing the score and information matrix can be 
found in the appendix. The estimate of η can then be iteratively obtained via  
2
( 1) ( )
( ) ( )




n n L L






where ηP(k+1)P and ηP(k)P are estimates obtained from the (k+1)PthP and kPthP iteration 
respectively. 
  
From the algorithm, the corresponding covariance matrix can also be 
obtained by taking the inverse of  
2
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21B3.3  Model checking 
 
27B3.3.1 Assessment of overall model adequacy 
 
Estimation of the parameters will be valid if the model is correctly 
specified or is adequate. Overall model adequacy can be checked via graphical 
techniques. We propose a graphical model checking method based on Cox-Snell 
residuals. The idea behind Cox-Snell residuals is that if the model fits well, the 
estimated model-based cumulative hazard should behave like a censored sample 
from an exponential distribution with rate 1. They can be derived as follows.  
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Let S(t) denote a survival function. Since 0 ≤ S(t) ≤ 1, let U = S(T). 
Therefore, 0 ≤ U ≤ 1 and T = SP-1P(U). Since U is uniform in [0,1], -log(U) is 
exponential with rate 1. However, note that -log(U) = -log(S(T)) = H(T). Hence, 
0( ; ) ( )exp( )
T
n n n nH T x H T x is the Cox-Snell residual for TRnR for subject n = 1,…, N. 
If the model is adequate, ( ; )n nH T x  will behave like a censored sample from an 




Model checking is implemented for times to the non-terminal event, as 
well as that for the terminal event with or without the prior occurrence of the non-
terminal event. Cox-Snell residuals are first obtained by computing their estimated 
cumulative hazards denoted by rRniR = ĤRiR(.), for subject n = 1,…, N and type of 
event i = 1, 2, 3. The cumulative hazards can be derived from the respective 
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(i) Non-terminal event 
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(ii) Terminal event without prior occurrence of non-terminal event 
1 2 2 2
1 2 2 2
1 2 2 2
2 2
1 2 2 2
1 2 2 2
1 2 2 2
( | , ) ( | , )
2 2
( | , ) ( | , )
2 2
2




{Pr( , | )}
{Pr( , | )}




1 ( ) ( )
w
w
H y w x H y w x
H y w x H y w x
Y y Y y
h y
Y y Y y
E Y y Y y w
E Y y Y y w
h y w x w dwe e g
w dwe e g
h y
where y




















  - 52 -  
(iii)  Terminal event following the occurrence of a non-terminal event   
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where y y 
 
 
Subsequently, the product-limit estimate of the cumulative hazard Ĥ(rRiR) for 
each event i = 1, 2, 3 can be computed from the censored sample (rRniR, δRniR). The 
plot of Ĥ(rRiR) against rRiR will approximately follow the 45P
o




28B3.3.2 Choice of model 
 
In order to determine whether a restrictive compartment model can be used 
in place of the general model, a likelihood ratio test can be used. As in Section 3.2, 
the parameter estimates in the general model are denoted by η = (θ, λR1R, γR1R, βR1R, λR2R, 
γR2R, βR2R, λR3R, γR3R, βR3R). A test of whether a restrictive model is adequate is equivalent to 
testing whether βR2R= βR3R, λR2R= λR3R, and γR2R= γR3R (that is, βR2R - βR3 R= 0, λR2 R-R RλR3R = 0, and γR2 R- 
γR3R = 0). This test can be carried out via the construction of contrasts. 
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The contrast matrix involving the 3 linear hypotheses is first written 
as
0 0 0 0 0 0 1 0 0 1
0 0 0 0 1 0 0 1 0 0






. After which, the likelihood ratio 










 and ''( )V U  . The statistic follows a chi-square distribution with 3 
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3BChapter 4: Simulation Studies 
 
 
22B4.1 Simulated data 
 
Simulation studies were conducted to assess the performance of the 
proposed method under different scenarios. For simplicity, we assumed that there 
was only one explanatory variable, treatment, which was coded as 1 or 0. Sample 
sizes of N = 200 and 300 were considered in the simulation studies. The covariate 
treatment was generated from a binomial distribution of size N with probability 
0.5; and YR1R and Y R2 Rwere generated from the compartment model in Section 3.1, 
where YR1R represented the time to relapse and YR2R represented the time to death. 
Throughout the simulation studies, the baseline hazard for relapse was of the form 
01 1( ) 2h y   where λR1R = 2 and γR1R = 1. Similarly, the baseline hazard for death 
without relapse was of the form 
02 2 2( ) 2h y y  where λR2R = 1 and γR2R = 2; and the 
baseline hazard for death after relapse (if applicable) was of the form 03 2( ) 1h y   
where λR3R = 1 and γR3R = 1. An independent administrative censoring time C was 
generated from a uniform distribution ~ Uniform (0, τ), where τ was a value 
chosen to yield censoring proportions of 30% and 50%.  
 
 Under the above-mentioned simulation settings, we evaluated the 
performance of the proposed method for different magnitudes of dependency 
between relapse and death. The parameter θ, which is associated with the 
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dependence structure, was varied to take values 0.5 representing weak dependence 
between relapse and death, 1 indicating moderate positive dependence and 2 
indicating large positive dependence. In addition, the performance of our model 
was evaluated under scenarios which considered an adverse, null or beneficial 
treatment effect on death. Under the general model formulation, we allowed the 
HR of relapse (denoted by HR RrelapseR = exp(βR1R)), and of death after relapse (denoted 
by HRRdeath_after_relapseR = exp(βR3R)) to take on values 0.5 or 1. The HR of death 
without any observation of relapse (denoted by HR Rdeath_without_relapseR = exp(βR2R)) was 
varied to take on values 0.5, 1 or 2. Under the restrictive model formulation, the 
HR of death, denoted by HR RdeathR = exp(βR2R), takes on values 0.5, 1 or 2. The 
treatment effect on relapse, (denoted by HRRrelapseR = exp(βR1R)) was assigned values 
of 0.5 and 1. 
  
The proposed approach was evaluated based on its bias, mean-squared 
error (MSE) and coverage probability (CP) at the nominal 95% level. For each 
simulation setting, 1000 replicates were generated. The MSEs were computed by 
taking the average of the squared bias resulting from the difference between the 
estimated and true parameter value. The coverage probability is the proportion of 
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23B4.2 Performance of proposed method 
 
UGeneral Compartment Model: 
Tables 3 to 6 present simulation results based on the General model 
obtained via NR algorithm, varying the effects of treatment on relapse (HRRrelapseR = 
0.5, 1), death without relapse (HRRdeath_without_relapseR = 0.5, 1, 2), or death after 
relapse (HRRdeath_after_relapseR = 0.5, 1). 
 
When there is no treatment effect, that is HR RrelapseR = HRRdeath_without_relapseR = 
HRRdeath_after_relapseR = 1, considering the simulation setting of n = 200 with 30% 
censoring, biases in the estimates are relatively close to zero as compared to the 
true parameter values with coverage probabilities approaching 95% for all degrees  
of dependence (θ) (Table 3).
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Table 3: Simulation results obtained from the General compartment model varying θ, exp(βR1R), exp(βR2R) and 
exp(βR3R) and constant λR1 R= 2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 200 with 30% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath_without_relapse R= 1 
HRRdeath_after_relapse R= 1 
HRRrelapse R= 1 
HRRdeath_without_relapse R= 2 











θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.072 0.247 94.9 -0.070 0.249 94.4 -0.054 0.196 95.4 -0.077 0.285 94.4 
 βR1 0.006 0.047 95.4 0.005 0.048 95.5 0.004 0.046 95.9 -0.003 0.053 96.3 
 βR2 -0.005 0.126 95.0 0.020 0.112 95.4 -0.021 0.147 95.7 -0.003 0.104 95.4 
 βR3 -0.005 0.065 95.7 -0.018 0.078 95.1 -0.011 0.067 95.7 -0.018 0.092 95.5 
 λR1 -0.002 0.037 94.8 -0.003 0.036 95.0 -0.001 0.034 95.4 -0.002 0.038 94.4 
 λR2 0.003 0.030 93.9 0.002 0.029 94.5 0.003 0.026 95.1 0.003 0.030 94.5 
 λR3 0.025 0.041 96.6 0.025 0.042 96.5 0.022 0.038 96.3 0.029 0.043 96.5 
 γR1 0.015 0.010 94.9 0.014 0.011 94.6 0.013 0.009 95.2 0.015 0.012 94.9 
 γR2 0.056 0.066 94.8 0.052 0.061 94.2 0.060 0.069 94.8 0.055 0.064 94.0 
 γR3 0.017 0.027 94.9 0.017 0.027 93.9 0.015 0.023 94.0 0.018 0.031 94.3 
1 θ -0.002 0.086 95.4 -0.002 0.073 96.0 -0.007 0.076 95.2 -0.004 0.089 95.3 
 βR1 0.003 0.070 93.4 0.002 0.073 93.9 0.004 0.069 93.2 -0.010 0.077 93.5 
 βR2 0.003 0.156 94.5 0.032 0.144 94.7 -0.013 0.180 95.4 0.001 0.139 94.3 
 βR3 0.021 0.089 94.7 0.004 0.101 94.6 0.006 0.087 95.3 -0.002 0.118 94.5 
 λR1 0.009 0.053 94.5 0.008 0.052 93.4 0.004 0.051 94.8 0.009 0.055 93.1 
 λR2 0.005 0.036 94.7 0.003 0.034 94.7 0.000 0.033 94.8 0.004 0.037 94.1 
 λR3 0.002 0.051 94.1 0.000 0.050 93.7 0.002 0.049 93.8 0.003 0.052 93.8 
 γR1 0.024 0.012 95.5 0.022 0.011 96.4 0.021 0.011 95.3 0.025 0.013 94.9 
 γR2 0.056 0.057 95.2 0.056 0.053 96.0 0.051 0.057 95.9 0.058 0.056 95.1 
 γR3 0.029 0.026 95.1 0.032 0.025 94.1 0.026 0.021 95.2 0.037 0.030 94.8 
2 θ 0.014 0.046 94.1 0.016 0.046 94.2 0.016 0.039 95.4 0.018 0.051 93.7 
 βR1 0.012 0.107 95.0 0.012 0.110 95.2 0.011 0.104 95.3 -0.004 0.116 95.7 
 βR2 0.013 0.190 95.0 0.037 0.184 95.9 -0.010 0.212 94.7 0.017 0.180 95.3 
 βR3 0.023 0.117 95.1 0.004 0.130 95.9 0.010 0.115 95.7 0.000 0.146 95.1 
 λR1 0.016 0.075 95.5 0.017 0.073 95.8 0.015 0.069 95.5 0.020 0.076 95.7 
 λR2 0.006 0.044 94.8 0.007 0.043 94.4 0.006 0.038 95.8 0.009 0.045 93.8 
 λR3 -0.002 0.057 95.4 -0.001 0.058 95.2 -0.004 0.057 94.7 0.001 0.059 95.6 
 γR1 0.027 0.015 94.7 0.027 0.015 94.8 0.025 0.013 95.0 0.030 0.017 94.9 
 γR2 0.056 0.060 94.2 0.053 0.055 95.1 0.057 0.055 94.5 0.059 0.056 95.6 
 γR3 0.030 0.024 94.6 0.031 0.024 94.3 0.028 0.021 95.6 0.035 0.029 94.6 
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In particular, large MSEs for θ, ranging from 0.196 to 0.285, are observed 
when θ = 0.5. However, the MSE decreases as θ increases. The CPs of all 
parameters remain relatively close to the nominal level of 95% for all values of θ 
considered. A large bias in the association parameter θ is also noted especially 
when there is a weak/ moderate association between the terminal and non-terminal 
events. This bias in the association parameter θ is most likely due to the fewer 
number of observations, and hence lesser amount of information, used to estimate 
θ when the association is weaker. However, the bias in θ decreases with an 
increase in sample size, as shown in Tables 3 to 6. Convergence problem was not 
encountered in the simulation studies and real data application. 
 
 When θ increases, there seem to be increases in MSEs for β1R and β3R, with 
MSEs for βR2R remaining relatively substantial. In particular, the increase in MSEs 
seems to have been contributed by an increase in variance of the covariates.  
Generally, when θ increases from 0.5 to 2, the standard errors for βs increase from 
0.2 to 0.4. The increase in standard errors in the βs is most likely influenced by the 
degree of dependence between the terminal and non-terminal events. There is no 
1-to-1 relationship between the βs and θ. Instead, it is mediated by the number of 
observations and the influence of θ on the βs. An increase in dependence increases 
the difficulty in estimating βs, as it brings about an additional source of variability. 
In the extreme case where there is zero dependence between the different event 
types, the βs would have been independent. Therefore, estimation of βs in such 
instances will be more straightforward, without the need to account for an extra 
source of variation in the parameter estimation.  
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With substantial association between relapse and death, the proportion of 
deaths occurring with prior relapse is usually large (in our study, it is about 70%). 
Not accounting for informative censoring of relapse by death is expected to 
produce biases in the estimates relating to relapse.  
 
In the same table (Table 3), it was shown that even when treatment has an 
effect on the risk of relapse, and death with or without prior relapse, the trends and 
magnitudes of the biases and MSEs of the parameter estimates are fairly similar to 
that observed when HRRrelapseR = HRRdeath_without_relapseR = HRRdeath_after_relapseR = 1.  
 
  With the exception of θ, conclusions drawn with regards to the biases and 
MSEs of β1, β2 and β3 do not change, when the proportion of censoring increased 
from 30% to 50% (Table 4). Under all simulation settings, a rather large MSE of θ, 
ranging from 0.442 to 0.661, was observed under weak dependence. These MSEs 
were considerably larger than those obtained when the proportion of censored 
observations was 30%. Also, the 95% coverage was not reached – it ranged from 
92.9% to 93.9%. However, a decreasing MSE for θ, together with CP 
approximating the 95% nominal level, is observed as θ increases. 
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Table 4: Simulation results obtained from the General compartment model varying θ, exp(βR1R), exp(βR2R) and 
exp(βR3R) and constant λR1 R= 2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 200 with 50% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath_without_relapse R= 1 
HRRdeath_after_relapse R= 1 
HRRrelapse R= 1 
HRRdeath_without_relapse R= 2 











θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.131 0.626 93.9 -0.119 0.563 93.4 -0.097 0.442 93.7 -0.123 0.661 92.9 
 βR1 0.007 0.051 95.1 0.006 0.052 95.6 0.004 0.050 95.3 -0.009 0.059 95.6 
 βR2 -0.011 0.154 95.5 0.020 0.131 96.5 -0.035 0.183 95.9 -0.016 0.123 96.6 
 βR3 -0.007 0.086 95.6 -0.028 0.106 95.7 -0.020 0.085 95.5 -0.036 0.130 95.7 
 λR1 0.005 0.048 94.4 0.004 0.046 94.3 0.004 0.043 94.6 0.010 0.048 95.3 
 λR2 0.011 0.041 95.1 0.010 0.040 94.5 0.008 0.036 94.4 0.016 0.041 94.5 
 λR3 0.033 0.053 96.9 0.032 0.053 97.2 0.031 0.046 96.8 0.038 0.058 96.8 
 γR1 0.021 0.014 94.3 0.020 0.014 93.6 0.019 0.012 94.4 0.024 0.016 93.7 
 γR2 0.073 0.091 94.3 0.069 0.082 95.1 0.071 0.091 94.7 0.074 0.084 95.5 
 γR3 0.027 0.042 92.7 0.025 0.043 94.1 0.021 0.034 94.6 0.030 0.051 93.8 
1 θ -0.014 0.166 93.9 -0.008 0.153 93.3 -0.013 0.138 94.1 -0.010 0.176 93.0 
 βR1 0.001 0.076 94.0 0.000 0.077 95.1 0.000 0.073 93.8 -0.018 0.085 94.3 
 βR2 0.008 0.189 94.5 0.031 0.174 95.0 -0.016 0.216 95.4 -0.001 0.165 95.7 
 βR3 0.022 0.107 95.0 0.002 0.124 95.7 0.008 0.105 95.3 -0.006 0.144 96.0 
 λR1 0.014 0.070 94.1 0.014 0.068 93.4 0.011 0.064 94.2 0.018 0.072 93.5 
 λR2 0.003 0.054 94.3 0.005 0.051 94.1 0.002 0.047 94.6 0.009 0.053 94.5 
 λR3 0.011 0.061 95.0 0.009 0.059 94.9 0.004 0.056 94.7 0.012 0.066 94.6 
 γR1 0.029 0.015 95.4 0.028 0.015 95.1 0.026 0.014 94.8 0.032 0.017 95.3 
 γR2 0.064 0.084 95.8 0.062 0.075 95.7 0.059 0.080 96.3 0.069 0.077 96.2 
 γR3 0.035 0.039 95.2 0.037 0.041 95.2 0.031 0.034 95.1 0.040 0.046 94.6 
2 θ 0.017 0.063 95.1 0.019 0.073 94.4 0.014 0.063 94.5 0.023 0.081 94.2 
 βR1 0.012 0.110 96.0 0.012 0.116 95.5 0.010 0.110 95.3 -0.008 0.122 95.3 
 βR2 0.020 0.215 95.3 0.043 0.218 95.3 -0.016 0.257 95.5 0.016 0.211 94.8 
 βR3 0.025 0.130 95.6 0.005 0.157 94.7 0.010 0.130 95.6 -0.003 0.176 95.2 
 λR1 0.021 0.081 95.1 0.024 0.088 94.2 0.019 0.080 95.3 0.030 0.092 94.6 
 λR2 0.005 0.053 94.3 0.008 0.059 94.5 0.003 0.052 95.1 0.013 0.061 94.6 
 λR3 0.001 0.063 95.5 0.005 0.065 96.1 0.002 0.062 95.8 0.007 0.065 96.3 
 γR1 0.031 0.017 94.4 0.033 0.018 94.5 0.029 0.016 93.9 0.037 0.020 95.2 
 γR2 0.064 0.077 95.2 0.065 0.080 94.6 0.063 0.082 94.1 0.071 0.079 94.7 
 γR3 0.035 0.032 94.2 0.034 0.036 94.6 0.035 0.032 94.5 0.041 0.041 94.9 
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Increasing the sample size from n = 200 to n = 300 improves the precision 
of the parameter estimates. In general, biases for all estimates are even closer to 
zero with the increase in sample size. Additionally, a notable decrease in MSEs of 
the estimates are observed. The 95% coverage probability is also reached for 
almost all estimates (Tables 5 and 6). 
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Table 5: Simulation results obtained from the General compartment model varying θ, exp(βR1R), exp(βR2R) and 
exp(βR3R), and constant λR1 R= 2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 300 with 30% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath_without_relapse R= 1 
HRRdeath_after_relapse R= 1 
HRRrelapse R= 1 
HRRdeath_without_relapse R= 2 











θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.027 0.125 96.3 -0.028 0.107 96.5 -0.023 0.104 95.5 -0.024 0.114 96.6 
 βR1 -0.001 0.033 94.8 -0.001 0.035 94.9 -0.002 0.033 94.7 -0.008 0.038 94.6 
 βR2 -0.007 0.082 94.3 0.004 0.073 95.2 -0.025 0.100 95.6 -0.004 0.071 94.4 
 βR3 0.000 0.046 94.4 -0.007 0.053 94.7 -0.010 0.045 95.2 -0.014 0.061 95.0 
 λR1 0.004 0.023 95.1 0.001 0.023 95.0 0.003 0.023 94.2 0.003 0.023 95.6 
 λR2 0.002 0.020 94.5 0.001 0.020 94.7 0.003 0.019 94.9 0.003 0.019 94.7 
 λR3 0.010 0.027 94.5 0.010 0.028 94.6 0.010 0.026 94.3 0.012 0.028 94.8 
 γR1 0.010 0.007 95.3 0.009 0.007 95.0 0.009 0.006 95.8 0.010 0.007 95.4 
 γR2 0.035 0.042 94.9 0.031 0.036 96.1 0.040 0.043 94.8 0.033 0.033 96.2 
 γR3 0.016 0.016 96.1 0.017 0.016 95.6 0.014 0.014 95.7 0.019 0.018 96.0 
1 θ 0.003 0.054 93.6 0.002 0.049 94.3 0.001 0.048 93.8 -0.002 0.057 94.5 
 βR1 0.014 0.041 95.3 0.013 0.042 94.9 0.014 0.040 95.7 0.005 0.047 95.9 
 βR2 0.004 0.096 95.4 0.016 0.088 96.0 -0.013 0.109 95.3 -0.001 0.084 95.7 
 βR3 0.015 0.057 95.0 0.010 0.065 95.1 0.004 0.055 95.2 0.004 0.079 95.0 
 λR1 -0.001 0.033 94.9 -0.002 0.032 95.1 -0.002 0.031 95.1 -0.003 0.035 94.5 
 λR2 0.005 0.023 94.9 0.004 0.021 95.4 0.004 0.021 94.7 0.004 0.023 94.7 
 λR3 -0.001 0.029 96.7 -0.002 0.029 96.7 -0.001 0.028 97.0 -0.001 0.029 96.7 
 γR1 0.016 0.008 95.1 0.014 0.008 95.0 0.015 0.007 95.1 0.015 0.009 94.7 
 γR2 0.042 0.039 95.2 0.041 0.037 95.1 0.039 0.038 94.2 0.039 0.039 94.6 
 γR3 0.020 0.017 95.2 0.020 0.016 94.4 0.017 0.015 94.5 0.021 0.019 94.7 
2 θ 0.011 0.033 93.6 0.017 0.031 93.2 0.008 0.029 93.6 0.015 0.035 92.8 
 βR1 0.009 0.068 94.9 0.011 0.070 94.7 0.008 0.067 94.5 -0.003 0.073 94.9 
 βR2 -0.005 0.130 95.2 0.015 0.127 95.8 -0.016 0.138 94.4 -0.006 0.118 94.8 
 βR3 0.001 0.090 93.4 -0.012 0.097 93.9 -0.009 0.086 93.7 -0.016 0.107 94.2 
 λR1 0.009 0.053 95.3 0.012 0.053 94.8 0.006 0.050 95.5 0.011 0.055 93.9 
 λR2 0.012 0.028 94.7 0.014 0.028 94.3 0.009 0.026 95.1 0.014 0.030 94.2 
 λR3 0.010 0.041 94.1 0.010 0.041 93.7 0.007 0.041 94.1 0.011 0.042 94.4 
 γR1 0.019 0.009 94.8 0.022 0.010 93.9 0.017 0.009 94.4 0.022 0.011 94.5 
 γR2 0.043 0.034 95.7 0.050 0.035 95.0 0.041 0.032 95.5 0.049 0.038 94.5 
 γR3 0.018 0.016 95.0 0.018 0.015 95.0 0.015 0.013 94.6 0.020 0.018 95.4 
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Table 6: Simulation results obtained from the General compartment model varying θ, exp(βR1R), exp(βR2R) and 
exp(βR3R), and constant λR1 R= 2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 300 with 50% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath_without_relapse R= 1 
HRRdeath_after_relapse R= 1 
HRRrelapse R= 1 
HRRdeath_without_relapse R= 2 











θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.056 0.233 95.3 -0.049 0.203 97.0 -0.034 0.181 95.8 -0.058 0.241 95.8 
 βR1 0.000 0.036 94.8 0.001 0.037 95.0 -0.001 0.035 94.5 -0.010 0.042 94.8 
 βR2 -0.002 0.104 95.3 0.009 0.087 95.6 -0.020 0.120 95.8 -0.003 0.087 94.9 
 βR3 0.003 0.061 94.8 -0.009 0.070 95.0 -0.010 0.058 95.4 -0.015 0.080 95.7 
 λR1 0.005 0.029 95.7 0.004 0.027 95.4 0.007 0.027 95.2 0.006 0.029 95.6 
 λR2 0.001 0.028 95.0 0.000 0.026 95.0 0.004 0.024 95.0 0.002 0.028 95.6 
 λR3 0.013 0.034 95.2 0.012 0.033 95.1 0.013 0.031 95.0 0.015 0.034 95.2 
 γR1 0.013 0.008 95.3 0.012 0.008 95.0 0.012 0.007 96.1 0.013 0.008 95.6 
 γR2 0.044 0.057 96.1 0.037 0.046 96.1 0.048 0.056 95.3 0.041 0.048 95.8 
 γR3 0.020 0.026 95.3 0.021 0.025 95.5 0.018 0.021 95.7 0.023 0.030 95.1 
1 θ -0.001 0.094 94.0 -0.002 0.081 94.8 0.007 0.073 93.8 -0.005 0.099 94.4 
 βR1 0.012 0.045 94.6 0.012 0.046 94.9 0.014 0.043 95.5 0.000 0.052 95.1 
 βR2 0.000 0.117 94.9 0.015 0.104 96.3 -0.016 0.138 95.1 -0.005 0.100 95.1 
 βR3 0.017 0.070 95.9 0.011 0.085 95.9 0.004 0.071 95.4 0.001 0.102 94.1 
 λR1 0.003 0.042 95.1 0.001 0.040 95.6 0.003 0.038 94.8 0.002 0.044 94.9 
 λR2 0.006 0.033 94.9 0.005 0.030 95.2 0.007 0.028 94.6 0.007 0.032 95.1 
 λR3 0.001 0.034 96.0 0.000 0.034 95.6 -0.001 0.032 96.1 0.004 0.035 95.7 
 γR1 0.019 0.010 94.3 0.017 0.010 94.9 0.019 0.009 95.5 0.019 0.011 94.1 
 γR2 0.047 0.057 95.3 0.043 0.049 95.4 0.046 0.055 94.6 0.044 0.053 94.9 
 γR3 0.024 0.025 94.7 0.026 0.028 95.1 0.023 0.023 95.0 0.028 0.032 94.7 
2 θ 0.020 0.044 94.6 0.025 0.046 94.2 0.017 0.044 94.2 0.024 0.055 94.0 
 βR1 0.009 0.072 94.6 0.011 0.074 94.5 0.008 0.070 94.9 -0.009 0.079 94.7 
 βR2 -0.014 0.148 94.5 0.006 0.152 94.7 -0.024 0.169 94.3 -0.015 0.142 95.5 
 βR3 -0.003 0.098 93.2 -0.015 0.111 94.4 -0.012 0.099 93.9 -0.027 0.127 93.7 
 λR1 0.017 0.060 95.5 0.022 0.061 95.1 0.015 0.060 94.9 0.022 0.065 94.8 
 λR2 0.019 0.035 94.5 0.023 0.037 94.0 0.017 0.035 94.7 0.022 0.040 94.5 
 λR3 0.013 0.043 95.4 0.015 0.043 95.4 0.013 0.043 95.4 0.017 0.044 95.6 
 γR1 0.024 0.011 94.3 0.027 0.012 94.9 0.022 0.011 94.2 0.028 0.013 94.9 
 γR2 0.055 0.046 95.6 0.062 0.050 95.4 0.055 0.049 95.4 0.061 0.054 95.0 
 γR3 0.025 0.020 94.8 0.028 0.023 94.7 0.024 0.019 94.8 0.032 0.027 95.2 
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URestrictive Compartment Model: 
Tables 7 to 10 present simulation results based on the Restrictive model 
obtained via the NR algorithm, varying the effects of treatment on relapse 
(HRRrelapseR = 0.5, 1) and on death (HRRdeathR = 0.5, 1, 2). 
 
When there is no treatment effect, that is HRRrelapseR = HRRdeathR = 1, 
considering the simulation setting of n = 200 with 30% censoring, biases in the 
estimates are relatively close to zero as compared to the true parameter values 
with coverage probabilities approaching 95% for all degrees of dependence (θ) 
(Table 7). The effect of treatment does not appear to have any influence on the 
magnitudes of the biases and MSEs of the parameter estimates.  
 
Similar to the General model, comparatively larger MSEs for θ, as 
compared to the other parameters, are observed when θ = 0.5. However, the MSE 
decreases as θ increases. The CPs of all parameters are close to the nominal level 
of 95% for all values of θ considered. In addition, the MSEs for β1R and β2R 
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Table 7: Simulation results obtained from the Restrictive compartment model varying θ, exp(β1R) and exp(β2R), λR1 = 
2, λR2R= 1R,  RλR3 = 1, γ1 R= 1R,  Rγ2 = 2, γR3 = 1 for n = 200 with 30% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath  R= 1 
HRRrelapse R= 1 
HRRdeath_ R= 2 
 
HRRrelapseR= 1 




HRRdeath_ R= 0.5 
 
θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.030 0.085 96.0 -0.028 0.087 97.3 -0.028 0.075 96.5 -0.031 0.087 96.3 
 βR1 -0.010 0.049 94.3 -0.010 0.052 95.3 -0.011 0.050 94.9 -0.018 0.054 94.9 
 βR2 -0.006 0.051 94.6 0.004 0.052 95.0 0.004 0.048 94.7 -0.016 0.054 94.0 
 λR1 0.012 0.029 94.4 0.011 0.030 95.1 0.010 0.028 94.6 0.011 0.029 94.6 
 λR2 0.000 0.007 94.3 0.001 0.008 94.3 0.000 0.007 94.3 0.000 0.007 94.3 
 γR1 0.012 0.007 95.4 0.011 0.007 95.3 0.010 0.007 94.9 0.011 0.007 95.2 
 γR2 0.026 0.024 94.9 0.026 0.024 95.1 0.023 0.022 94.4 0.026 0.024 94.9 
1 θ -0.004 0.042 94.9 -0.001 0.044 95.3 -0.004 0.041 95.2 -0.005 0.044 94.8 
 βR1 0.001 0.062 95.6 0.000 0.064 95.5 -0.001 0.063 95.9 -0.010 0.066 95.9 
 βR2 -0.010 0.063 95.0 -0.004 0.069 94.7 0.000 0.065 94.9 -0.014 0.066 95.0 
 λR1 0.006 0.039 94.9 0.007 0.039 95.1 0.006 0.038 94.6 0.006 0.038 94.5 
 λR2 0.009 0.009 95.4 0.010 0.009 95.0 0.008 0.009 94.7 0.008 0.009 94.6 
 γR1 0.014 0.008 94.0 0.014 0.009 93.5 0.013 0.008 93.7 0.014 0.009 93.3 
 γR2 0.020 0.026 94.9 0.021 0.026 94.2 0.020 0.025 94.6 0.020 0.026 94.4 
2 θ 0.006 0.026 95.2 0.005 0.026 95.0 0.003 0.025 94.4 0.004 0.027 94.4 
 βR1 0.007 0.096 94.8 0.006 0.101 94.6 0.004 0.098 95.0 -0.008 0.104 94.0 
 βR2 -0.001 0.096 95.7 0.009 0.098 95.5 0.008 0.097 95.5 -0.013 0.098 96.3 
 λR1 0.002 0.062 93.7 0.002 0.062 93.1 0.001 0.061 93.5 0.002 0.061 93.6 
 λR2 0.004 0.014 94.8 0.004 0.014 94.9 0.003 0.014 94.9 0.004 0.014 95.1 
 γR1 0.017 0.008 94.2 0.017 0.009 93.6 0.016 0.009 93.9 0.017 0.009 94.0 
 γR2 0.034 0.026 94.3 0.034 0.026 94.5 0.032 0.024 94.8 0.034 0.026 95.2 
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The conclusions drawn with regards to the biases and MSEs of θ, β1 Rand β2R 
remained similar to those obtained under the General model setting, when the 
proportion of censoring increased from 30% to 50% (Table 8). Under weak 
dependence, a comparatively larger MSE of θ in relation to the other parameters, 
ranging from 0.087 to 0.165, was observed. However, the CP was rather 
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Table 8: Simulation results obtained from the Restrictive compartment model varying θ, exp(β1R) and exp(β2R), λR1 R= 
2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 200 with 50% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath  R= 1 
HRRrelapse R= 1 
HRRdeath_ R= 2 
 
HRRrelapseR= 1 




HRRdeath_ R= 0.5 
 
θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.040 0.130 95.2 -0.049 0.165 95.2 -0.029 0.102 96.1 -0.031 0.087 96.3 
 β1 -0.011 0.052 94.6 -0.011 0.057 95.1 -0.010 0.054 95.1 -0.018 0.054 94.9 
 βR2 -0.010 0.059 94.7 0.002 0.065 94.4 0.003 0.056 94.9 -0.016 0.054 94.0 
 λR1 0.014 0.031 94.6 0.012 0.034 95.3 0.012 0.031 95.1 0.011 0.029 94.6 
 λR2 0.000 0.009 93.5 -0.001 0.011 94.6 0.001 0.009 94.4 0.000 0.007 94.3 
 γR1 0.014 0.008 96.0 0.014 0.008 95.8 0.013 0.008 95.1 0.011 0.007 95.2 
 γR2 0.029 0.029 95.3 0.028 0.031 96.1 0.029 0.027 95.6 0.026 0.024 94.9 
1 θ -0.011 0.065 94.7 -0.012 0.066 94.9 -0.008 0.052 95.1 -0.005 0.044 94.8 
 βR1 -0.002 0.066 95.8 -0.001 0.070 95.9 -0.001 0.066 96.1 -0.010 0.066 95.9 
 βR2 -0.014 0.072 95.6 -0.002 0.077 95.7 -0.002 0.071 95.5 -0.014 0.066 95.0 
 λR1 0.007 0.044 94.7 0.005 0.045 94.5 0.005 0.041 95.2 0.006 0.038 94.5 
 λR2 0.010 0.010 95.7 0.009 0.011 95.6 0.008 0.010 95.5 0.008 0.009 94.6 
 γR1 0.015 0.009 94.4 0.014 0.010 95.4 0.013 0.009 94.1 0.014 0.009 93.3 
 γR2 0.025 0.033 94.1 0.025 0.034 94.2 0.021 0.029 94.9 0.020 0.026 94.4 
2 θ 0.010 0.035 95.9 0.009 0.038 94.8 0.006 0.031 95.3 0.004 0.027 94.4 
 βR1 0.006 0.101 95.3 0.004 0.108 95.1 0.003 0.105 94.4 -0.008 0.104 94.0 
 βR2 0.001 0.108 96.0 0.016 0.114 95.6 0.011 0.106 95.7 -0.013 0.098 96.3 
 λR1 0.008 0.067 94.2 0.006 0.069 93.1 0.005 0.065 93.7 0.002 0.061 93.6 
 λR2 0.006 0.016 94.7 0.004 0.017 94.9 0.004 0.015 94.6 0.004 0.014 95.1 
 γR1 0.021 0.010 93.5 0.020 0.011 94.2 0.019 0.010 94.6 0.017 0.009 94.0 
 γR2 0.041 0.035 95.2 0.040 0.036 94.9 0.037 0.030 94.8 0.034 0.026 95.2 
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Increasing the sample size from n = 200 to n = 300 improves the precision 
of the parameter estimates. In general, biases for all estimates are even closer to 
zero with the increase in sample size. Additionally, a notable decrease in MSEs of 
the estimates are observed. The 95% coverage probability is also reached for 
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Table 9: Simulation results obtained from the Restrictive compartment model varying θ, exp(β1) and exp(β2), λR1 R= 
2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 300 with 30% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath  R= 1 
HRRrelapse R= 1 
HRRdeath_ R= 2 
 
HRRrelapseR= 1 




HRRdeath_ R= 0.5 
 
θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.017 0.057 95.1 -0.020 0.062 96.1 -0.019 0.052 95.7 -0.023 0.061 96.1 
 βR1 0.010 0.032 95.0 0.012 0.034 95.3 0.012 0.032 95.3 0.009 0.035 94.9 
 βR2 0.004 0.035 93.3 0.007 0.037 94.3 0.008 0.034 94.2 0.000 0.036 93.9 
 λR1 -0.005 0.019 94.8 -0.004 0.019 94.9 -0.005 0.018 94.5 -0.006 0.019 95.0 
 λR2 0.000 0.005 94.8 0.001 0.005 94.5 0.000 0.004 95.1 0.000 0.004 95.1 
 γR1 0.005 0.005 93.6 0.006 0.005 95.1 0.005 0.005 95.0 0.006 0.005 95.2 
 γR2 0.013 0.015 95.7 0.013 0.016 94.8 0.012 0.014 96.3 0.010 0.015 95.7 
1 θ -0.006 0.028 95.6 -0.007 0.029 94.6 -0.008 0.026 95.1 -0.006 0.030 95.7 
 βR1 -0.008 0.045 94.6 -0.010 0.046 95.1 -0.009 0.045 94.8 -0.013 0.047 94.9 
 βR2 -0.013 0.043 95.2 -0.004 0.044 95.5 -0.003 0.043 95.3 -0.018 0.044 95.2 
 λR1 0.005 0.024 95.8 0.004 0.024 96.0 0.004 0.024 95.5 0.005 0.024 95.4 
 λR2 0.003 0.006 95.0 0.002 0.006 94.5 0.002 0.006 94.7 0.003 0.006 94.6 
 γR1 0.006 0.004 96.2 0.005 0.004 96.4 0.006 0.004 96.3 0.006 0.004 96.9 
 γR2 0.018 0.015 95.7 0.019 0.015 95.8 0.018 0.014 96.6 0.018 0.015 95.7 
2 θ 0.006 0.016 95.5 0.006 0.016 96.1 0.007 0.015 96.1 0.006 0.016 95.0 
 βR1 -0.011 0.067 95.1 -0.015 0.070 94.9 -0.013 0.069 95.1 -0.021 0.072 95.0 
 βR2 -0.006 0.067 94.9 0.002 0.070 94.4 0.000 0.069 94.5 -0.015 0.067 95.3 
 λR1 0.009 0.040 93.8 0.009 0.040 94.2 0.007 0.039 94.1 0.007 0.040 94.3 
 λR2 0.004 0.009 95.5 0.003 0.009 95.4 0.003 0.009 95.4 0.003 0.009 95.5 
 γR1 0.011 0.005 95.9 0.010 0.005 96.0 0.009 0.005 95.7 0.009 0.005 95.9 
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Table 10: Simulation results obtained from the Restrictive compartment model varying θ, exp(βR1R) and exp(βR2R), λR1 
R= 2, λR2 R= 1R,  RλR3  R= 1, γR1 R= 1R,  RγR2 R= 2, γR3 R= 1 for n = 300 with 50% censoring. 
 
  
HRRrelapse R= 1 
HRRdeath  R= 1 
HRRrelapse R= 1 
HRRdeath_ R= 2 
 
HRRrelapseR= 1 




HRRdeath_ R= 0.5 
 
θ  BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) BIAS MSE CP(%) 
0.5 θ -0.024 0.081 96.3 -0.029 0.103 95.6 -0.024 0.072 96.0 -0.029 0.099 95.6 
 βR1 0.012 0.034 95.0 0.013 0.037 93.8 0.012 0.035 94.6 0.008 0.039 95.1 
 βR2 0.000 0.041 93.7 0.008 0.044 94.5 0.005 0.039 94.6 -0.005 0.046 93.5 
 λR1 -0.004 0.020 95.3 -0.003 0.022 95.9 -0.004 0.020 95.5 -0.003 0.021 95.1 
 λR2 0.002 0.006 93.9 0.001 0.007 94.5 0.002 0.005 94.3 0.002 0.006 93.8 
 γR1 0.007 0.006 94.7 0.008 0.006 94.3 0.006 0.005 95.6 0.007 0.006 94.5 
 γR2 0.015 0.018 94.9 0.015 0.020 94.8 0.014 0.017 95.3 0.015 0.020 94.7 
1 θ -0.004 0.044 94.4 -0.006 0.045 94.6 -0.004 0.035 95.5 -0.005 0.047 94.5 
 βR1 -0.009 0.048 94.9 -0.009 0.049 95.4 -0.009 0.047 94.7 -0.015 0.052 94.8 
 βR2 -0.009 0.050 95.2 -0.002 0.050 96.6 -0.002 0.046 95.7 -0.016 0.052 95.3 
 λR1 0.007 0.028 95.6 0.005 0.028 95.6 0.005 0.026 95.4 0.006 0.028 95.7 
 λR2 0.003 0.007 94.4 0.002 0.008 94.7 0.002 0.007 94.4 0.002 0.007 94.6 
 γR1 0.008 0.005 95.6 0.007 0.005 95.3 0.007 0.005 95.6 0.008 0.005 96.7 
 γR2 0.023 0.020 94.9 0.022 0.020 95.4 0.019 0.017 95.9 0.022 0.020 94.9 
2 θ 0.005 0.024 95.4 0.005 0.024 95.9 0.004 0.020 96.0 0.005 0.024 95.6 
 βR1 -0.015 0.069 95.3 -0.020 0.073 94.8 -0.016 0.071 94.7 -0.025 0.074 95.5 
 βR2 -0.007 0.076 94.8 0.000 0.080 94.5 0.003 0.074 93.8 -0.016 0.076 95.6 
 λR1 0.011 0.044 93.5 0.011 0.045 94.6 0.008 0.042 94.4 0.008 0.043 95.0 
 λR2 0.002 0.011 95.8 0.002 0.011 95.6 0.001 0.010 95.6 0.002 0.010 95.3 
 γR1 0.013 0.006 95.2 0.012 0.006 96.1 0.010 0.005 96.3 0.010 0.006 96.1 
 γR2 0.024 0.021 95.3 0.022 0.022 95.1 0.021 0.018 95.8 0.022 0.021 95.1 
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Similar to the General model, while the MSE of θ is relatively large under 
weak dependence, it decreases when θ increases. In addition, the MSEs of the 
estimates for treatment effects increase as θ increases. Nonetheless, the 
magnitudes of the MSE in the restrictive model are by and large smaller than 
those observed in the General model. Coverage probabilities of 95% are reached 
for all parameters in the Restrictive model on the whole. In the Restrictive model, 
an increase in the biases and MSEs of θ is observed when the proportion of 
censoring of death increases from 30% to 50%, regardless of the magnitude of 
treatment effect. However, the increase in the proportion of censored observations 
seemed to have little effect on the biases and MSEs of the other parameters. As 
the proportion of censored observations increase, a corresponding increase in the 
magnitude of biases and MSEs of the other parameters was also experienced. An 
increase in sample size also decreases the magnitude of the biases and MSEs of 
all parameters, which is similar to the conclusions drawn if the General model 
was used.  
 
To summarize, estimates of the degree of dependence between relapse and 
death are subjected to a greater bias and MSE if the underlying dependence is 
weak. Estimates of the treatment effects are probably less precise if the degree of 
dependence is at least moderate. It was noted that as θ increases, the variances of 
the covariates, in particular, increase. CPs are generally close to the nominal level 
of 95% for all simulation settings based on the Restrictive and General model. 
MSEs of small to moderate magnitudes are also observed for the parameters. 
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Hence, our simulation studies suggest that parameters estimated via our proposed 
method are relatively unbiased with small to moderate variances, depending on 
the degree of dependence.   
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Chapter 5: Application to the nasopharyngeal cancer 
clinical trial dataset 
 
 
 The incidence of nasopharyngeal cancer (NPC) among males hovered 
at a numerical value of 14 per 100,000 person-years in the period from 1968-1972 
to 1993-1997, until it showed a decline in 1998-2002. A similar trend was 
observed among females where the incidence remained at about 6.0 per 100,000 
person-years from 1968-1972 to 1993-1997, before decreasing to 3.7 per 100,000 
person-years in 1998-2002. Despite showing a decline, NPC is by far one of the 
most frequently occurring cancers among Singaporeans, and  one of the most 
common causes of death among cancer patientsP
39
P Hence, there is a need to 
explore treatment regimes for NPC.  
 
 Radiotherapy (RT) is expected to cure about 50% of patients inflicted 
with NPC. It is estimated that about 30% of patients will develop loco-regional 
recurrence after a full course of RT, and half of the patients with very large and/or 
supraclavicular lymph nodes will relapse distantly. P
40
P Chemotherapy has been 
used to treat metastatic or recurrent NPC, with overall response rates of 50-80% 
with the use of platinum based combinations. In the adjuvant setting, however, the 
results have been controversial.  
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 Therefore, a randomized clinical trial on NPC was conducted in 
Singapore to assess the therapeutic intervention of standard RT versus concurrent 
chemo-radiotherapy followed by adjuvant chemotherapy.P
4
P Eligible patients who 
were diagnosed with stage III or IV (non-metastatic) NPC were recruited between 
September 1997 and May 2003 following informed consent. Patients who had 
previous treatment for NPC, signs of distant metastasis, and other concomitant 
malignant disease were excluded from the trial. A total of 221 patients were 
randomly assigned to receive only radiotherapy (RT; n = 110) or concurrent 
chemo-radiotherapy followed by adjuvant chemotherapy (CRT; n = 111). For 
patients on CRT, they were treated with concurrent cisplatin (CDDP) and RT 
before proceeding on to adjuvant CDDP and fluorouracil (FU). Dose schedules 
for patients on CRT are presented in Table 11. All patients were required to be 
followed up every 4 months for the first year, every 6 months for the second and 
third year and every year thereafter. The median follow-up time was reported to 
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 Typically, patients with NPC will undergo RT and/or CRT treatment, 
and then enjoy a disease-free period. During the course of treatment, they may 
develop a distant metastasis (disease-spread usually at the lung or the bone) or a 
local recurrence. It is also possible that the patient may even die before any of 
these events has occurred, for example from pneumonia or a treatment related 
cause such as neutropenic sepsis. 
 
 In this trial, two endpoints were of interest – time to relapse and time 
to mortality. Although death was the primary outcome, relapse was also 
considered to be an important endpoint because it has been found that a 
substantial proportion of patients with Stage III or IV endemic NPC relapsed 
locoregionally and/or systematically with RT alone.  
 
  Altogether, there were 75 relapses. Of these, 20 patients remained alive 
without any evidence of disease and 55 died following a relapse. In addition, there 
were 13 deaths without a prior relapse being reported. Table 12 gives a 
breakdown of the events which have occurred in each treatment group.  
 
Table 12: Breakdown of events in the CRT and RT groups 
Type of event occurred CRT RT Total 
Relapse, and then death 
 
16 39 55 
Death without relapse 
 
8 5 13 
Relapse without death 11 9 20 
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 With a substantial number of deaths following relapse, it is anticipated that 
death (terminal event) may be strongly related to relapse (non-terminal event). As 
a consequence, a semi-competing risks approach, which is intended to account for 
the correlation between relapse and death, will be appropriate for analyzing such 
data following a natural order of disease progression. Our proposed methodology 
was thus applied to the NPC data, by modeling the dependence between the 
relapse and death times via the frailty approach. 
 
Parameter estimates describing the relationship for relapse and death in the 
NPC dataset for the General Compartment model are presented in Table 13. A 
positive dependence structure was observed between relapse and death times, 
with an association parameter of 6.79 (95% CI: 3.70, 12.46). This indicates that 
relapse is highly associated with death. After accounting for the dependence 
between relapse and death, patients on CRT were observed to be at a lower risk of 
death after relapse than those on RT, with a HR = exp(βR3R) of 0.47 although this 
was not significant (95% CI: 0.15, 1.48). Among patients without relapse, patients 
on CRT were observed to be at a slightly higher risk of death than those on RT 
with a HR = exp(βR2R) of 1.26, but this difference was not significant (95% CI: 0.31, 
5.10). The HR of relapse comparing patients on CRT and those on RT = exp(βR1R) 
is 0.44 (95% CI: 0.16, 1.20). The shape parameters were also observed to be 
greater than 1, and were statistically significant. This suggests that the risk of a 
relapse or death increased over time. The risk of death increased, regardless of 
whether there was a previous occurrence of relapse. 
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Table 13: Parameter estimates based on the proposed General Compartment 





Estimate 95% CI exp(Estimate) (95% CI) 
θ’ 1.92 (1.31, 2.52) 6.79 (3.70, 12.46) 
βR1 -0.82 (-1.82, 0.18)  0.44 (0.16, 1.20)P
†
 
βR2 0.23 (-1.18, 1.63)  1.26 (0.31, 5.10)P
†
 
βR3 -0.75 (-1.89, 0.39)  0.47 (0.15, 1.48)P
†
 
 λ1’ -0.24 (-0.77, 0.29)  0.79 (0.47, 1.34) 
 λ2’ -1.44 (-2.60, -0.28)  0.24 (0.07, 0.75) 
 λ3’ -0.72 (-1.04, -0.40)  0.49 (0.35, 0.67) 
γ1’ 0.74 (0.42, 1.06) 2.10 (1.53, 2.89) 
γ2’ 0.61 (0.16, 1.06) 1.84 (1.17, 2.90) 
γ3’ 0.97 (0.64, 1.30) 2.64 (1.91, 3.68) 
P
†
P: Corresponds to hazards ratio (HR) 
 
 
The adequacy of our model was checked via Cox-Snell residuals. The 
following figures show the residuals for the event times in each of the 3 paths of 
the general compartment model.  
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Figure 6: Cox-Snell residuals for time to relapse, times to death without prior 
relapse, and following relapse based on the general compartment model 
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It was observed that the residuals for the path to relapse in the General 
compartment model generally lie closely on the line of identity, indicating an 
adequate model fit. However, there appears to be a slight deviation from the line 
of identity in the Cox-Snell residuals at the tail-end distribution of death times 
without relapse. The deviation is most likely to be contributed by individuals who 
were followed for a much longer period of time exceeding 5 years, without 
experiencing any relapse or death. In the same plot, we also noticed a “step-like” 
function. The study sample involved in this second plot are patients who were 
uncensored on both events (n = 133) and those who experienced only death (n = 
13). Hence, the “steps” are likely due to the substantial proportion of subjects 
being censored on both events – relapse and death. It was also noted that small 
residuals of magnitude very much less than 3 were observed for relapse and death 
without relapse. This could be due to the high probability of relapse and death 
without relapse. There were 75 relapses out of 220 patients, with 48 and 27 
relapses in RT and CRT groups respectively. When recurrence-free survival was 
considered, median time to relapse was reached at 4.1 years for the RT group. 
Patients on the CRT arm did not reach median relapse-free survival. Among 
patients who did not experience any relapse, median survival was not reached in 
any of the RT or CRT groups. A lack of fit was also observed for the path from 
relapse to death, since residuals did not fall near to the line of identity. The lack of 
fit could have come about when we constrained the shapes and scales for the 
baseline hazards for each treatment group to be the same for each compartment 
arm. When a sub-group analysis was performed for each RT and CRT group, a 
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difference in the shape parameters for relapse to death arm comparing between 
RT and CRT was observed. While a shape parameter of 3.75 (95% CI: 2.65, 5.30) 
was observed in the RT group, a shape parameter of 1.04 (95% CI: 0.32, 3.41) 
was observed in the CRT group. As the shape parameters are statistically greater 
than 1 among the patients on CRT and RT, it suggests that the risk of relapse and 
death both increase over time among these 2 groups of patients. Results are 
presented in Tables 14 and 15. 
 
Table 14: Parameter estimates based on the proposed General Compartment 





Estimate 95% CI exp(Estimate) (95% CI) 
θ’ 1.86 (1.16, 2.56) 6.42 (3.19, 12.95) 
 λR1R’ -0.13 (-0.66, 0.41) 0.88 (0.52, 1.51) 
 λR2R’ -1.19 (-2.31, -0.07) 0.30 (0.10, 0.94) 
 λR3R’ -0.71 (-0.97, -0.44) 0.49 (0.38, 0.64) 
γR1’ 0.84 (0.45, 1.24) 2.32 (1.56, 3.45)  
γR2’ 0.72 (0.12, 1.33) 2.06 (1.12, 3.79) 
γR3’ 1.32 (0.98, 1.67) 3.75 (2.65, 5.30) 
 
Table 15: Parameter estimates based on the proposed General Compartment 






Estimate 95% CI exp(Estimate) (95% CI) 
θ’ 2.28 (1.50, 3.06) 9.77 (4.46, 21.37) 
 λR1R’ -0.53 (-1.22, 0.15) 0.59 (0.30, 1.16) 
 λR2R’ -1.18 (-2.30, -0.06) 0.31 (0.10, 0.94) 
 λR3R’ -1.05 (-1.93, -0.17) 0.35 (0.15, 0.84) 
γR1’ 0.80 (0.29, 1.31) 2.23 (1.33, 3.71) 
γR2’ 0.67 (0.04, 1.30) 1.95 (1.04, 3.66) 
γR3’ 0.04 (-1.15, 1.23) 1.04 (0.32, 3.41) 
 
We further attempted to demonstrate that the scale parameter is similar 
between CRT and RT, while the shape parameter differs between the 2 treatment 
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groups via another alternative method. In this alternative method, we estimated 









  respectively. From these 2 equations, we 
allowed the scale and shape parameters to vary with the covariate x, where x is the 
treatment covariate (given by CRT coded as 1; RT coded as 0) in this study. 
While the magnitude of the scale is similar between CRT and RT (βR3R = -1.05 – (-
0.71) = -0.34; 95% CI: -0.26, 0.57), the shape parameter differs between the 2 
treatment groups ( *
3 = log(1.04) - log(3.75) = -1.28; 95% CI: -2.52, -0.04). Hence, 
this suggests that the shape parameter for CRT is exp(-1.28) = 0.28 times that for 
RT in the relapse to death pathway in the compartment model, which corresponds 
to what we have observed in Tables 14 and 15. 
 
A special case of the General Model, which imposes more restrictive 
assumptions of βR2 R= βR3R and hR02 R= hR03R, was also considered. A likelihood ratio test 
comparing βR2 R= βR3R, as well as parameters relating to the hazards namely γR2 R= γR3R 
and λR2 R= λR3R simultaneously using the chi-square test statistic with 3 degrees of 
freedom as described in Section 3.3.2, shows that equality holds for all 3 sets of 
parameters ( 2(3)  = 0.922; p = 0.82). Hence, it suggests that a reduced Restrictive 
model is sufficient for describing the data. The adequacy of the restrictive model 
was also checked via the Cox-Snell residuals in Figure 7. A lack of fit was also 
observed for the patients who died, regardless of whether they experienced a 
relapse. However, the inadequacy of model fit was more apparent in the relapse to 
death path of the compartment model. 
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Figure 7: Cox-Snell residuals for time to relapse and to death based on the 
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Under this Restrictive Model, it is shown that patients on CRT have a 
lower risk of death as compared to those on RT, regardless of whether they had a 
prior relapse (HR = exp(βR2R) = 0.59; 95% CI: 0.19, 1.82). In addition, patients on 
CRT have a lower risk of relapse as compared to those on RT (HR = exp(βR1R) = 
0.42; 95% CI: 0.14, 1.27). The amount of relatedness between relapse and death 
was quantified by an association parameter of 8.96 (95% CI: 6.31, 12.72) (Table 
16).  
 
When both the General and Restrictive models were implemented, the HR 
of relapse comparing CRT and RT patients were similar (HR of 0.44 based on the 
General model versus 0.42 based on the Restrictive model). The HR of death 
could not be directly compared between the two models, as we have allowed the 
hazards of death to vary after relapse for the General model. While the Restrictive 
model may be valid for the data from the likelihood ratio test, the General model 
probably provided more information on the hazards of death on the disease 
process in the NPC data. It was observed that treatment seemed to have a different 
impact on the risk of death among patients who have suffered a relapse, and those 
who had not. While it was observed that patients on CRT had a higher risk of 
death before relapse than those on RT alone (HR = 1.26; 95% CI: 0.31, 5.10), a 
protective effect was observed among patients who had relapsed (HR = 0.47, 95% 
CI: 0.15, 1.48). However, it should be noted that the elevated risk of death 
without relapse should be interpreted with caution, as there were only 13 deaths 
without relapse out of 220 patients. The Restrictive model showed that CRT 
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lowered the risk of death as compared to RT in general (HR = 0.59; 95% CI: 0.19, 
1.82). A substantial degree of correlation between relapse and death was observed, 
when both models were used. 
 
In a previous analysis where the association between relapse and death has 
not been taken into consideration and disease-free survival (DFS) was the 
outcome of interest, the HR comparing patients on CRT and RT was 0.57 (95% 
CI: 0.38, 0.87).P
4
P A re-analysis of the data showed that when recurrence-free 
survival was of interest, the HR was 0.51 (95% CI: 0.32, 0.82). When overall 
survival was the outcome of interest, the HR was 0.51 (95% CI: 0.31, 0.81).P
4
P 
While the magnitudes of the HR for death were similar using the restrictive 
compartment model or the Cox proportional hazards assuming non-informative 
censoring, a slightly larger protective treatment effect for relapse was conferred 
by the restrictive compartment model. However, whereas statistical significance 
was achieved in the analyses by Wee et alP
4
P, significance was not reached using 
either of the current parametric models.  
 
Table 16: Parameter estimates based on the proposed Restrictive 






Estimate 95% CI exp(Estimate) (95% CI) 
θ’ 2.19 (1.84, 2.54) 8.96 (6.31, 12.72) 
βR1 -0.87 (-1.98, 0.24) 0.42 (0.14, 1.27)P
† 
βR2 -0.53 (-1.65, 0.60) 0.59 (0.19, 1.82)P
† 
λ1’ -0.05 (-0.39, 0.30) 0.95 (0.67, 1.34)P
  
λ2’ -0.70 (-1.01, -0.38) 0.50 (0.36, 0.68) 
γ1’ 0.93 (0.72, 1.13) 2.52 (2.06, 3.09) 
γ2’ 0.99 (0.79, 1.20) 2.70 (2.20, 3.32) 
P
†
P: Corresponds to hazards ratio (HR) 
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5BChapter 6: Discussion and Concluding remarks  
 
 
In biomedical studies, it is often of interest to evaluate the efficacy of 
treatment in a clinical trial or the effect of covariates such as stage of cancer. 
Although death is an important endpoint, investigation of intermediate events, 
such as relapse, are also essential as they provide additional information 
pertaining to the disease progression process. In the ATAC trial data example, 
while 60% of the patients died after recurrence, the remaining 40% of the patients 
died without recurrence and from other causes. Although it is anticipated that 
recurrence is a relatively strong indicator for death, some of the death causes may 
not be disease-related, and therefore not strongly predicted by recurrence. 
Therefore, it will also be useful to know whether reducing morbidity will reduce 
mortality to the same extent. And if the effects of treatment are different for the 
two different types of outcomes (morbidity and mortality), it will be of interest to 
quantify the relative efficacy of treatment on both mortality and morbidity.  
 
In addition, in cancer trials such as ATAC, radiotherapy is one of the usual 
treatment options for cancer patients. Although radiotherapy may be able to 
improve patient survival, its effect on normal tissue is not known. It will then be 
relevant to quantify the effect of the intermediate event (toxicity) by radiation, 
while accounting for the effect of radiotherapy on overall survival. P
25
P Therefore, 
this further corroborates the importance of looking at intermediate events in a 
disease progression process.  
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The type of survival data as mentioned above, where both morbidity (non-
terminal event) and mortality (terminal event) are of analytical importance, has 
been defined earlier in this thesis as semi-competing risks data. Due to the lack of 
an appropriate methodology, semi-competing risks data are sometimes analyzed 
based on a competing risks framework where treatment efficacy is evaluated 
using only first-event information from each individual, ignoring all subsequent 
events that follow. In this instance, apart from describing the events using 
cumulative incidence functionsP
15,43
P, Cox proportional hazards model is also 
frequently fitted to obtain the cause-specific hazard ratio estimate of the exposure 
for each event conditional on surviving all other failure types. While this first-
event only approach eliminates the need to address the association between 
multiple event times for the same subject, it is inefficient because it does not 
utilize all the available informationP
44
P. This postulate is supported in a study by 
Tai et alP
45
P,  which showed discrepancies in hazard ratio estimates between 
methods which consider only the first event that occurs, and those that utilize 
information on all subsequent events. The discrepancies were magnified in 
instances when event times are highly correlated, or when the relative mean 
lifetime of the events are about equal. Besides, based on the competing risks 
paradigm, the dependence structure and the marginal distributions are not 
identifiable.P
46
P Although much effort has been devoted to bounding the 
marginalsP
47-49
P, these methods are complex and have assumptions that are not 
testable.  
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In view of the association between relapse and death, appropriate 
methodologies will be needed to profile the risk of morbidity and mortality over 
time more realistically, with emphasis on the non-terminal event. This need to 
map morbidity on the disease progression was corroborated by Fine et al.
7
. In 
comparison to their method which considers the association between the non-
terminal and terminal events, it was observed that the Kaplan-Meier method 
consistently overestimated the survival curve for relapse. As a consequence, 
appreciable differences in the estimates for covariates can occur depending on 
whether dependent censoring has been accounted forP
18,26,31
P This is illustrated by a 
difference in treatment effect for relapse in the NPC data as presented in Chapter 
5 of this thesis, which was observed to be intensified as compared to the effects 
obtained by the naive Cox proportional hazards model assuming non-informative 
censoring in Wee et alP
4
P. In a similar study on nasopharyngeal cancer by Xu et 
alP
31
P, which accounts for possible dependence between relapse and death via a 
non-parametric approach, a reduced risk of relapse was also observed in patients 
on CRT as compared with RT. In the latter study, the log-hazards of relapse 
among patients on CRT was -0.82 (SE: 0.34) times as much as those on RT. The 
log-hazards of death and relapse-to-death among patients on CRT were 0.14 (SE: 
0.53) and -0.74 (SE: 0.35) times as much as patients on RT respectively. Their 
estimates were similar to those obtained in this thesis (Table 13), which suggested 
robustness of the parameter estimates against misspecification in the baseline 
hazard form. In another study by PengP
18
P, it was noted that the risk of first 
virologic failure amongst patients on Efavirenz (EFV) was 0.66 (Estimate (SE): -
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0.416 (0.222)) times that of those on Nelfinavir (NFV) when Cox proportional 
hazards model was used without taking potentially dependent censoring of first 
virologic failure by death into account. When dependent censoring was 
considered, the estimate (SE) of the treatment effect became -0.487 (0.226), 
indicating that EFV put patients at a much lower risk of first virologic failure as 
compared to NFV (39% as compared to the previous 34%). Similarly, in the 
National Surgical Adjuvant Breast and Bowel Project (NSABP)P
26
P, a difference in 
the effect of Tamoxifen on local-regional failure was observed, depending on 
whether possible dependent censoring of local-regional failure by distant failure, 
second primary cancers and non-cancer deaths was considered. When possible 
dependence was ignored, a HR of 0.411 (95% CI: 0.312, 0.541) was achieved. 
Accounting for possible dependence resulted in a HR of 0.528 (95% CI: 0.444, 
0.627). 
 
Methods for analyzing semi-competing risks data were proposed 
following Fine et alP
7
P. Assuming that the form of the marginal distribution for the 
time to the non-terminal event is known, approaches involving copula models and 
marginal distributions for the non-terminal event under weak assumptions have 
been put forth. However, in contrast to previous studies which have made 
assumptions about the marginal distribution for the time to the non-terminal 
outcome, no such assumption is made in this study and we limit our analysis to 
the observable region of the data. With observed pairs of morbidity and mortality 
data, we introduced a new method for semi-competing risks data to account for 
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the dependence structure between morbidity and mortality, while estimating their 
respective hazard functions using a frailty approach. We used the Clayton 
(gamma frailty) copula model in the joint modeling of morbidity and mortality 





P copulas may be adopted. We have not 
checked for the appropriateness in the usage of the Clayton copula model P
26
P, but it 





With the frailty model, covariate effects can be directly interpreted with 
explicit modeling of the baseline hazards via Cox proportional hazards model 
together with the association parameter between morbidity and mortality. This 
approach is similar to Xu et alP
31
P, Peng and FineP
18
P as well as Hsieh and WangP
30
. 
However, differences in the formulation of the regression models exist. While 
baseline hazards were assumed to be governed by a parametric form (Weibull 
distribution) in this thesis, a non-parametric method was used to describe the 
baseline hazards in Xu et al.P
31
P Although non-parametric hazards may offer more 
robust covariate estimates, parametric distributions offer a direct description of 
baseline hazards. Moreover, model fit could be easily checked using graphical 
techniques as suggested in Section 3. Furthermore, while Cox proportional 
hazards model was adopted for regression purposes in this thesis, Peng and Fine P
18
P 
as well as Hsieh and WangP
30
P, used a flexible monotone function, which 
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incorporates proportional hazards model as a special case, to describe the 
functional form for morbidity.  
 
Among other differences in the model formulation as compared to 
previous methods, we have also allowed for model parameters to vary depending 
on the state of disease progression. This is illustrated by the construction of the 
compartment model in Section 3.1. Apart from varying effects of covariates on 
outcomes based on whether the patient has a previous occurrence of morbidity 
(e.g. relapse), baseline hazards also varied according to the progression of disease. 
This approach is generally more flexible than other methods proposed previously. 
This is because we think that the risk of death are likely to be different among 
patients who have experienced a relapse than those who have not, and this 
correlation between relapse and death may not have been fully accounted for by 
frailty. Therefore, the unaccounted “excess” correlation will be manifested as a 
difference in model parameterizations in the compartment model as shown in 
Section 3.1. Previous methods have assumed that any dependency between the 
non-terminal and terminal events has been fully captured by frailty. Hence, the 
strength of our method lies in the adoption of a more general model formulation 
according to the state of disease. A test of model parameters can also be 
performed, in order to determine if a less complex model results.   
 
Computation of the model parameter estimates can be easily achieved 
using the NR algorithm. Simulation studies attested to the performance of the 
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proposed method, with small MSEs and CPs close to the nominal level. Checks of 
overall model adequacy are available with the implementation of the proposed 
method. One technique, such as that involving graphical assessment of the Cox-
Snell residuals, has been suggested to establish model fit here. Through the Cox-
Snell residuals, it was shown that a lack of fit was observed in the relapse-to-
death path of the compartment model for NPC data. This was possibly due to the 
difference in the shape parameters governing the baseline hazards for the relapse-
to-death arm in both RT and CRT, as shown by the subgroup analyses in Chapters 
5. However, for the proposed model in this thesis, we have imposed the constraint 
that the shape and scale parameters determining the baseline hazards only depend 
on the pathway of the compartment model and not on the covariate (treatment). 
Nevertheless, we believe that if the baseline hazards were correctly specified, the 
proposed model would work well in practical settings, as attested by the 
simulation results. Hence, other models with more suitable parametric baseline 
hazards could be considered when a lack of fit in the data was observed. 
  
The importance of accounting for the dependency between relapse and 
death was shown in both the simulated and NPC datasets. The magnitude of the 
dependency serves as an indication of the predictive value that an occurrence of 
relapse will have on death. If the dependency is strong, it implies that an 
occurrence of relapse will increase the risk of mortality substantially. Conversely, 
if the dependency is almost negligible, then it suggests that the prognostic outlook 
will probably not change even if a relapse were to occur. Referring to the scenario 
 - 94 - 
relating to relapse and death at the beginning of this chapter, if there was indeed 
an association of substantial magnitude between these two events, it would then 
be necessary to develop or adopt appropriate treatment strategies which could 
lower the chances of relapse, since it would influence the progression to death. 
 
The proposed compartment model fits the structure of semi-competing 
risks data nicely, and provides an interpretable estimation of the covariate effects 
on morbidity. However, one limitation of the compartment model is that while the 
overall survival probability for the terminal event can be estimated using 
conventional methods, the survival probability for the non-terminal outcomes is 
not estimable as we do not assume that the form of the distribution on the lower 
wedge (where the non-terminal is censored by the terminal event) to be known. 
 
The current compartment model may be generalized to accommodate 
other forms of settings. In the proposed compartment model approach, we have 
assumed only one non-terminal event occurring before the terminal event. 
However, scenarios may arise which warrant investigation of the inter-
relationships between more than one non-terminal event, in addition to the 
possible occurrence of the terminal event. Local recurrence has been 
demonstrated to be an important indicator for metastasis; and survival patterns for 
metastatic breast cancer patients depend on whether local recurrence has occurred 
previously. However, prognostic outlooks may be different for women who have 
metastases at different anatomical locationsP
50
P Hence, it will be useful to explore 
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how the current proposed model can be further generalized to take into account all 
possible types of clinically important intermediate events which can occur before 
the occurrence of the terminal event.  
 
The current model also assumes that the covariate effects and the 
parameter estimates are time-invariant. However, the dependence between event 
times, as well as the covariate effects, may vary over time. Therefore, studies on 
how to employ techniques involving time-dependent copulas, such as that 
proposed in Peng and Fine
18
P, for modeling the dependence between non-terminal 
and terminal event times will be required. Furthermore, the current compartment 
model was proposed for right-censored data, such as that observed in a usual 
clinical trials setting. However, data subjected to left truncation and right 
censoring, such as those involving registries, may arise
27
P Hence, it will be useful 
to investigate how the current proposed model can be extended to accommodate 
data of this structure.  
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